

SECURITIES AND EXCHANGE COMMISSION

FORM 10-Q

Quarterly report pursuant to sections 13 or 15(d)

Filing Date: **2021-03-11** | Period of Report: **2021-01-31**
SEC Accession No. [0001493152-21-005819](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

Anixa Biosciences Inc

CIK: **715446** | IRS No.: **112622630** | State of Incorporation: **DE** | Fiscal Year End: **1031**
Type: **10-Q** | Act: **34** | File No.: **001-37492** | Film No.: **21733719**
SIC: **2834** Pharmaceutical preparations

Mailing Address

3150 ALMADEN
EXPRESSWAY, SUITE 250
SAN JOSE CA 95118

Business Address

3150 ALMADEN
EXPRESSWAY, SUITE 250
SAN JOSE CA 95118
408-708-9808

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2021

Commission file number 001-37492

ANIXA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

11-2622630

(I.R.S. Employer
Identification No.)

3150 Almaden Expressway, Suite 250
San Jose, CA

(Address of principal executive offices)

95118

(Zip Code)

(408) 708-9808

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading symbol</u>	<u>Name of exchange on which registered</u>
Common Stock, par value \$.01 per share	ANIX	NASDAQ Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Non-accelerated filer

Smaller reporting company

Accelerated filer

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [] No [X]

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

On March 11, 2020 the registrant had outstanding 26,705,514 shares of Common Stock, par value \$.01 per share, which is the registrant's only class of common stock.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements.	3
	Condensed Consolidated Balance Sheets as of January 31, 2021 (Unaudited) and October 31, 2020	3
	Condensed Consolidated Statements of Operations (Unaudited) for the three months ended January 31, 2021 and 2020	4
	Condensed Consolidated Statements of Shareholders' Equity (Unaudited) for the three months ended January 31, 2021 and 2020	5
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended January 31, 2021 and 2020	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations.	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	25
Item 4.	Controls and Procedures.	25

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings.	26
Item 1A.	Risk Factors.	26
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	26
Item 3.	Defaults Upon Senior Securities.	26
Item 4.	Mine Safety Disclosures.	26
Item 5.	Other Information.	26
Item 6.	Exhibits.	26

	SIGNATURES	27
--	----------------------------	----

PART I. FINANCIAL INFORMATION**Item 1. Financial Statements.****ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES**
CONDENSED CONSOLIDATED BALANCE SHEETS

	(Unaudited)	
	January 31, 2021	October 31, 2020
<u>ASSETS</u>		
Current assets:		
Cash and cash equivalents	\$ 11,982,870	\$ 6,417,061
Short-term investments in certificates of deposit	2,000,000	2,640,000
Prepaid expenses and other current assets	581,320	311,563
Total current assets	<u>14,564,190</u>	<u>9,368,624</u>
Operating lease right-of-use asset	40,212	54,340
Other assets	-	30,000
Total assets	<u>\$ 14,604,402</u>	<u>\$ 9,452,964</u>
<u>LIABILITIES AND EQUITY</u>		
Current liabilities:		
Accounts payable	\$ 511,816	\$ 232,368
Accrued expenses	972,835	901,025
Operating lease liability	40,836	55,198
Total current liabilities	<u>1,525,487</u>	<u>1,188,591</u>
Commitments and contingencies (Note 9)		
Equity:		
Shareholders' equity:		
Preferred stock, par value \$100 per share; 19,860 shares authorized; no shares issued or outstanding	-	-
Series A convertible preferred stock, par value \$100 per share; 140 shares authorized; no shares issued or outstanding	-	-
Common stock, par value \$.01 per share; 100,000,000 shares authorized; 26,179,122 and 24,248,695 shares issued and outstanding, respectively	261,791	242,486
Additional paid-in capital	207,382,102	200,354,488
Accumulated deficit	(194,043,909)	(191,835,618)
Total shareholders' equity	<u>13,599,984</u>	<u>8,761,356</u>
Noncontrolling interest (Note 1)	(521,069)	(496,983)
Total equity	<u>13,078,915</u>	<u>8,264,373</u>
Total liabilities and equity	<u>\$ 14,604,402</u>	<u>\$ 9,452,964</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	For the Three Months Ended January 31,	
	2021	2020
Revenue	\$ 512,500	\$ -
Operating costs and expenses:		
Inventor royalties, contingent legal fees, litigation and licensing expenses	385,002	-
Research and development expenses (including non-cash share-based compensation expenses of \$290,207 and \$397,523, respectively)	827,651	1,490,588
General and administrative expenses (including non-cash share-based compensation expenses of \$695,892 and \$623,811, respectively)	1,532,978	1,139,281
Total operating costs and expenses	<u>2,745,631</u>	<u>2,629,869</u>
Loss from operations	(2,233,131)	(2,629,869)
Interest income	754	13,294
Net loss	(2,232,377)	(2,616,575)
Less: Net loss attributable to noncontrolling interest	<u>(24,086)</u>	<u>(24,032)</u>
Net loss attributable to common shareholders	<u>\$ (2,208,291)</u>	<u>\$ (2,592,543)</u>
Net loss per common share attributable to common shareholders:		
Basic and diluted	<u>\$ (0.09)</u>	<u>\$ (0.13)</u>
Weighted average common shares outstanding:		
Basic and diluted	<u>25,164,565</u>	<u>20,703,882</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

FOR THE THREE MONTHS ENDED JANUARY 31, 2021 (UNAUDITED)

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Shareholders' Equity	Non- controlling Interest	Total Equity
	Shares	Par Value					
Balance, October 31, 2020	24,248,695	\$ 242,486	\$ 200,354,488	\$ (191,835,618)	\$ 8,761,356	\$ (496,983)	\$ 8,264,373
Stock option compensation to employees and directors	-	-	874,862	-	874,862	-	874,862
Stock options and warrants issued to consultants	-	-	111,237	-	111,237	-	111,237
Common stock issued upon exercise of stock options	29,880	299	103,925	-	104,224	-	104,224
Common stock issued in at-the-market offering, net of offering expenses of \$184,510	1,900,547	19,006	5,937,590	-	5,956,596	-	5,956,596
Net loss	<u>-</u>	<u>-</u>	<u>-</u>	<u>(2,208,291)</u>	<u>(2,208,291)</u>	<u>(24,086)</u>	<u>(2,232,377)</u>
Balance, January 31, 2021	<u>26,179,122</u>	<u>\$ 261,791</u>	<u>\$ 207,382,102</u>	<u>\$ (194,043,909)</u>	<u>\$ 13,599,984</u>	<u>\$ (521,069)</u>	<u>\$ 13,078,915</u>

FOR THE THREE MONTHS ENDED JANUARY 31, 2020 (UNAUDITED)

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Shareholders' Equity	Non- controlling Interest	Total Equity
	Shares	Par Value					
Balance, October 31, 2019	20,331,754	\$ 203,317	\$ 186,849,299	\$ (181,817,263)	\$ 5,235,353	\$ (422,975)	\$ 4,812,378
Stock option compensation to employees and directors	-	-	963,880	-	963,880	-	963,880
Stock options issued to consultants	-	-	57,454	-	57,454	-	57,454
Common stock issued upon exercise of stock options	18,900	189	28,291	-	28,480	-	28,480
Common stock issued in at-the-market offering, net of offering expenses of \$100,972	490,655	4,907	1,747,076	-	1,751,983	-	1,751,983
Net loss	-	-	-	(2,592,543)	(2,592,543)	(24,032)	(2,616,575)
Balance, January 31, 2020	<u>20,841,309</u>	<u>\$ 208,413</u>	<u>\$ 189,646,000</u>	<u>\$ (184,409,806)</u>	<u>\$ 5,444,607</u>	<u>\$ (447,007)</u>	<u>\$ 4,997,600</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	For the three months ended January 31,	
	2021	2020
Cash flows from operating activities:		
Reconciliation of net loss to net cash used in operating activities:		
Net loss	\$ (2,232,377)	\$ (2,616,575)
Stock option compensation to employees and directors	874,862	963,880
Stock options and warrants issued to consultants	111,237	57,454
Depreciation of property and equipment	-	14,998
Gain on sale of equipment	(5,447)	-
Amortization of operating lease right-to-use asset	14,128	12,314
Change in operating assets and liabilities:		
Prepaid expenses and other current assets	(269,757)	74,698
Accounts payable	279,448	(218,719)
Accrued expenses	71,810	(190,464)
Operating lease liability	(14,362)	(12,002)
Net cash used in operating activities	<u>(1,170,458)</u>	<u>(1,914,416)</u>
Cash flows from investing activities:		
Disbursements to acquire short-term investments in certificates of deposit	(1,000,000)	(1,870,000)
Proceeds from maturities of short-term investments in certificates of deposit	1,640,000	1,350,000
Purchase of property and equipment	-	(15,790)
Proceeds from sale of equipment	35,447	-
Net cash provided by (used in) investing activities	<u>675,447</u>	<u>(535,790)</u>
Cash flows from financing activities:		
Net proceeds from sale of common stock in at-the-market offering	5,956,596	1,751,983
Proceeds from exercise of stock options	104,224	28,480
Net cash provided by financing activities	<u>6,060,820</u>	<u>1,780,463</u>
Net increase (decrease) in cash and cash equivalents	5,565,809	(669,743)
Cash and cash equivalents at beginning of period	6,417,061	3,491,625
Cash and cash equivalents at end of period	<u>\$ 11,982,870</u>	<u>\$ 2,821,882</u>

Supplemental cash flow information:

Cash proceeds from interest income	\$	1,134	\$	14,468
------------------------------------	----	-------	----	--------

The accompanying notes are an integral part of these condensed consolidated financial statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

1. BUSINESS AND FUNDING

Description of Business

As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Our primary operations involve developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. Our therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (“CAR-T”) technology, initially focused on treating ovarian cancer, and discovery and ultimately development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Our vaccine programs include the development of a vaccine against breast cancer, specifically triple negative breast cancer (“TNBC”), the most lethal form of the disease, and a vaccine against ovarian cancer.

Our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”) relating to Wistar’s CAR-T technology. We have initially focused on the development of a treatment for ovarian cancer, but we may also pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent (5%) of the common stock of Certainty.

Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), is advancing toward human clinical testing its CAR-T technology for treating ovarian cancer. We are currently testing the clinical grade vector and preparing an Investigational New Drug (“IND”) application for submission to the U.S. Food and Drug Administration (“FDA”). We anticipate filing the IND in the first calendar quarter of 2021. Assuming the FDA approves our IND application, we anticipate beginning the human clinical trials during the second half of 2021.

In April 2020, we entered into a collaboration with OntoChem GmbH (“OntoChem”), to discover and ultimately develop anti-viral drug candidates against COVID-19. Through this collaboration, we utilized advanced computational methods, machine learning, and molecular modeling techniques to perform *in silico* screening of over 1.2 billion compounds in chemical libraries (including publicly available compounds and OntoChem’s proprietary libraries) to evaluate if any of these compounds could disrupt one of two key enzymes of SARS-CoV-2, the virus that causes the disease COVID-19.

The screening process resulted in the identification of multiple compounds that could potentially disrupt critical enzymes of the virus. Several of these compounds were synthesized and tested in *in vitro* biological assays. Upon completion of these biological assays, we identified two of the most promising compounds and have begun testing them in animal models. In these animal studies, the two compounds are being compared to Remdesivir, which is the only anti-viral drug authorized by the FDA for COVID-19. We anticipate this proof-of-concept animal study to be completed by the end of the first calendar quarter of 2021.

We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. We are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused

specifically on TNBC. A specific protein, alpha-lactalbumin, has been identified that is only present during lactation in healthy women, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. In December 2020, we received authorization from the FDA to commence enrollment and treatment of patients in a Phase 1a clinical trial. We are performing the activities necessary to prepare for treatment of patients in the Phase 1a clinical trial, and we anticipate being prepared to treat the first enrolled patient by mid-year 2021.

In November 2020, we executed a license agreement with Cleveland Clinic pursuant to which the Company was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. This technology pertains to the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor II protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines after menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. We entered into a joint development agreement with Cleveland Clinic, to advance this vaccine technology toward human clinical testing.

Over the next several quarters, we expect the development of our breast and ovarian cancer vaccines, our COVID-19 therapeutic program and Certainty’s CAR-T technology to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities regarding the Cchek™ liquid biopsy platform (operations for which were suspended in July 2020), as well as in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management.

Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and vaccine programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin generating revenue with respect to any of our current therapy or vaccine programs in the near term. We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as therapeutics or vaccines. The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials.

Funding and Management’s Plans

Based on currently available information as of March 11, 2021, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. During the three months ended January 31, 2021, we raised approximately \$5,957,000, net of expenses, through an at-the-market equity offering of 1,900,547 shares of common stock, under which offering we may issue up to \$50 million of common stock. Under our at-the-market equity program which is currently effective and may remain available for us to use in the future, as of January 31, 2021, we may sell an additional approximately \$34,670,000 of common stock. We may seek to obtain working capital during our fiscal year 2021 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt could result in dilution to our stockholders. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2020. The accompanying October 31, 2020 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of January 31, 2021, and results of operations and cash flows for the interim periods represented. The results of operations for the three months ended January 31, 2021 are not necessarily indicative of the results to be expected for the entire year.

Noncontrolling Interest

Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2021:

Balance, October 31, 2020	\$ (496,983)
Net loss attributable to noncontrolling interest	(24,086)
Balance, January 31, 2021	<u>\$ (521,069)</u>

Revenue Recognition

Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive.

We follow the accounting guidance of Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. In accordance with ASC 606 we are required to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time.

Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.

Cost of Revenues

Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations.

Research and Development Expenses

Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, preventative cancer vaccines and anti-viral drug candidates for COVID-19, are expensed in the accompanying condensed consolidated financial statements in the period incurred.

2. STOCK BASED COMPENSATION

The Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants.

Stock Option Compensation Expense

The compensation cost for service-based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to four years. We recorded stock-based compensation expense related to service-based stock options granted to employees and directors of approximately \$875,000 and \$964,000 during the three months ended January 31, 2021 and 2020.

For stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company's common stock exceeding certain price targets, we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). On May 8, 2018, we issued market condition options to purchase 1,500,000 shares of common stock, to our Chairman, President and Chief Executive Officer, vesting at target trading prices of \$5.00 to \$8.00 per share before May 31, 2021, with implied service periods of three to seven months. In October 2018, the first tranche of 500,000 shares of market condition options became exercisable upon achieving an average closing price above \$5.00 per share for twenty consecutive trading days. We did not record any market condition stock-based compensation expense during the three months ended January 31, 2021 and 2020.

The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately \$54,000 and \$57,000 during the three months ended January 31, 2021 and 2020, respectively.

Stock Option Plans

During the three months ended January 31, 2021, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the "2010 Share Plan") and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the "2018 Share Plan"), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018.

During the three months ended January 31, 2020, the remaining outstanding options under the Anixa Biosciences, Inc. 2003 Share Incentive Plan (the "2003 Plan") expired.

Stock Option Activity

During the three months ended January 31, 2021 and 2020, we granted options to purchase 1,130,000 shares and 800,000 shares of common stock, respectively, to employees and consultants, with exercise prices ranging from \$2.83 to \$4.04 per share, pursuant to the 2018 Share Plan. During the three months ended January 31, 2021 and 2020, stock options to purchase 29,880 and 18,900 shares of common stock, respectively, were exercised with aggregate proceeds of approximately \$104,000 and \$28,000, respectively.

2003 Plan

The 2003 Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2003 Plan, the plan terminated

with respect to the ability to grant future awards on April 21, 2013. Information regarding the 2003 Plan for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2019	400	\$ 17.00	
Forfeited/Expired	(400)	\$ 17.00	
Options outstanding and exercisable at January 31, 2020	-	\$ -0-	\$ -0-

11

2010 Plan

The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020. Information regarding the 2010 Share Plan for the three months ended January 31, 2021 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2020	1, 1,907,534	\$ 2.82	
Exercised	(6,000)	\$ 2.32	
Forfeited/Expired	(400)	\$ 5.75	
Options outstanding at January 31, 2021	1 1,901,134	\$ 2.82	\$ 1,906,253
Options exercisable at January 31, 2021	1, 1,823,634	\$ 2.83	\$ 1,822,053

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2021:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 0.67 - \$ 2.30	544,000	5.22	\$ 1.56	516,500	5.15	\$ 1.60
\$ 2.58 - \$ 3.13	833,000	3.11	\$ 2.79	833,000	3.54	\$ 2.79
\$ 3.46 - \$ 5.30	524,134	7.11	\$ 4.17	474,134	7.07	\$ 4.25

Information regarding the 2010 Share Plan for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options Outstanding at October 31, 2019	1,998,668	\$ 2.80	
Exercised	(18,900)	\$ 1.51	
Forfeited/Expired	(5,534)	\$ 2.58	
Options Outstanding at January 31, 2020	1,974,234	\$ 2.81	\$ 1,810,395
Options Exercisable at January 31, 2020	1,721,734	\$ 2.86	\$ 1,542,195

12

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2020:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 0.67 - \$2.30	561,500	6.28	\$ 1.56	464,000	6.03	\$ 1.69
\$ 2.58 - \$ 3.13	878,200	3.43	\$ 2.79	878,200	3.97	\$ 2.79
\$ 3.46 - \$ 5.75	534,534	7.94	\$ 4.16	379,534	7.76	\$ 4.45

2018 Plan

The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of January 31, 2021, the 2018 Share Plan had 2,000,000 shares available for future grants. Information regarding the 2018 Share Plan for the three months ended January 31, 2021 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2020	4,346,661	\$ 3.69	
Granted	1,130,000	\$ 2.83	
Exercised	(23,880)	\$ 3.78	
Forfeited/Expired	(392,781)	\$ 3.70	
Options outstanding at January 31, 2021	5,060,000	\$ 3.49	\$ 1,184,900
Options exercisable at January 31, 2021	2,312,640	\$ 3.69	\$ 147,579

The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2021:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 2.09 - \$3.70	3,975,000	8.12	\$ 3.38	1,664,862	7.47	\$ 3.61
\$ 3.84 - \$4.61	1,085,000	7.95	\$ 3.90	647,778	7.66	\$ 3.92

Information regarding the 2018 Share Plan for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options Outstanding at October 31, 2019	3,935,500	\$ 3.74	
Granted	800,000	\$ 3.85	
Options Outstanding at January 31, 2020	4,735,000	\$ 3.76	\$ -0-
Options Exercisable at January 31, 2020	1,798,616	\$ 3.74	\$ -0-

The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2020:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 3.70	3,100,000	8.27	\$ 3.70	1,433,334	8.27	\$ 3.70
\$ 3.84 - \$4.61	1,635,000	9.17	\$ 3.88	365,282	8.32	\$ 3.92

Outside of Share Plans

In addition to options granted under stock option plans, during the years ended October 31, 2012 and 2013, the Board of Directors approved the grant of stock options to certain employees and directors. Information regarding stock options that were granted outside of share plans for the three months ended January 31, 2021 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2020	1,698,000	\$ 2.58	
Options outstanding and exercisable at January 31, 2021	1,698,000	\$ 2.58	\$ 1,825,350

The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2021:

Range of Exercise Prices	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 2.58	1,698,000	1.56	\$ 2.58

Information regarding stock options that were granted outside of Share Plans for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2019	1,698,000	\$ 2.58	
Options outstanding and exercisable at January 31, 2020	1,698,000	\$ 2.58	\$ 1,655,550

The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2020:

Range of Exercise Prices	Number Outstanding	Weighted Average	Weighted Average
--------------------------	--------------------	------------------	------------------

	and Exercisable	Remaining Contractual Life (in years)	Exercise Price
\$ 2.58	1,698,000	2.50	\$ 2.58

Stock Awards

For stock awards granted to employees, directors and consultants that vest upon grant we recognize expense at the date of grant based on the grant date market price of the underlying common stock. We did not grant any stock awards that vested upon grant during the three months ended January 31, 2021 or 2020.

On May 8, 2018, a restricted stock award of 1,500,000 shares of common stock was granted under the 2018 Share Plan to our Chairman, President and Chief Executive Officer. The restricted stock award vests in its entirety upon achievement of a target trading price of \$11.00 per share of the Company's common stock before May 31, 2021. For restricted stock awards vesting upon achievement of a price target of our common stock we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). We did not record any compensation expense related to the restricted stock award during the three months ended January 31, 2021 and 2020.

Employee Stock Purchase Plan

The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan ("ESPP") which permits eligible employees to purchase shares at not less than 85% of the market value of the Company's common stock on the offering date or the purchase date of the applicable offering period, whichever is lower. The plan was adopted by our Board of Directors on August 13, 2018 and approved by our shareholders on September 27, 2018. During the three months ended January 31, 2021 and 2020, no shares were purchased under the ESPP.

Warrants

On October 30, 2020 we issued a warrant, expiring on October 30, 2025, to purchase 60,000 shares of common stock at \$2.06 per share, vesting over five months, to a consultant for investor relations services. We recorded consulting expense of approximately \$57,000 during the three months ended January 31, 2021, based on the fair value of the warrant on the date of grant recognized on a straight-line basis over the vesting period. We did not record any consulting expense related to warrants during the three months ended January 31, 2020. No warrants were issued during the three-month periods ended January 31, 2021 and 2020.

As of January 31, 2021, we also had warrants outstanding to purchase 500,000 shares of common stock at \$5.03 per share, issued during fiscal year 2017 and expiring on November 30, 2021.

3. FAIR VALUE MEASUREMENTS

US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date.

Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.

Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities.

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of January 31, 2021:

	Level 1	Level 2	Level 3	Total
Money market funds:				
Cash and cash equivalents	\$ 11,568,608	\$ -	\$ -	\$ 11,568,608
Certificates of deposit:				
Cash and cash equivalents	250,000	-	-	250,000
Short-term investments	-	2,000,000	-	2,000,000
Total financial assets	\$ 11,818,608	\$ 2,000,000	\$ -	\$ 13,818,608

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2020:

	Level 1	Level 2	Level 3	Total
Money market funds:				
Cash and cash equivalents	\$ 3,902,292	\$ -	\$ -	\$ 3,902,292
Certificates of deposit:				
Cash and cash equivalents	2,250,000	-	-	2,250,000
Short-term investments	-	2,640,000	-	2,640,000
Total financial assets	\$ 6,152,292	\$ 2,640,000	\$ -	\$ 8,792,292

Our non-financial assets that are measured on a non-recurring basis include our other assets which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value.

4. ACCRUED EXPENSES

Accrued expenses consist of the following as of:

	January 31, 2021	October 31, 2020
Payroll and related expenses	\$ 228,163	\$ 415,331
Accrued royalty and contingent legal fees	577,190	449,691
Accrued collaborative research and license expense	147,410	30,000
Accrued other	20,072	6,003
	\$ 972,835	\$ 901,025

5. NET LOSS PER SHARE OF COMMON STOCK

Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the three months ended January 31, 2021 and 2020, were stock options to purchase 8,659,134 and 8,407,234 shares, respectively, and warrants to purchase 560,000 and 500,000 shares, respectively.

6. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-02 (“ASU 2016-02”) Accounting Standards Codification Topic 842, Leases (ASC 842), which supersedes Topic 840, Leases, and which requires lessees to recognize most leases on the balance sheet. The new lease standard does not substantially change lessor accounting. For public companies, the standard was effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption was permitted. Lessees and lessors were required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance. In July 2018, FASB issued ASU 2018-11, Leases, which provides an additional transition option for an entity to apply the provisions of ASC 842 by recognizing a cumulative effect adjustment at the effective date of adoption without adjusting the prior comparative periods presented. The requirements of this standard include a significant increase in required disclosures. The Company adopted ASU 2016-02 on November 1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. See Note 8 regarding the accounting and disclosures related to our office lease.

7. INCOME TAXES

We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets.

We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have no unrecognized income tax benefits as of January 31, 2021 and October 31, 2020 and we account for interest and penalties related to income tax matters, if any, in general and administrative expenses.

8. LEASES

We lease approximately 2,000 square feet of office space at 3150 Almaden Expressway, San Jose, California (our principal executive offices) from an unrelated party pursuant to an operating lease that expires September 30, 2021. Our base rent is approximately \$5,000 per month and the lease provides for annual increases of approximately 3% and an escalation clause for increases in certain operating costs. Rent expense was approximately \$16,000 and \$16,000, respectively, for the three months ended January 31, 2021 and 2020.

On November 1, 2019, the Company adopted ASC 842, which increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (“ROU”) assets and related operating lease liabilities on the balance sheet. The Company adopted the new guidance using the modified retrospective approach on November 1, 2019.

The Company elected the package of practical expedients permitted within the standard, which allow an entity to forgo reassessing (i) whether a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has also elected the short-term lease accounting policy under which Anixa would not recognize a lease liability or ROU asset for any lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that Anixa is more than reasonably certain to exercise.

For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The remaining 8-month lease term as of January 31, 2021 for the Company’s lease includes the noncancelable period of the lease. The lease does not contain a Company option to extend the lease or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment.

Balance sheet information related to the Company's lease is presented below:

	Balance Sheet Location	January 31, 2021	October 31, 2020
Operating Lease:			
Right-of-use asset	Operating lease right-of-use asset	\$ 40,212	\$ 54,340
Right-of-use liability, current	Operating lease liability	40,836	55,198

As of January 31, 2021, the annual minimum lease payments of our operating lease liabilities were as follows:

	Operating Leases
2021 future minimum payments, undiscounted	\$ 43,008
Less: Imputed interest	(2,172)
Present value of future minimum lease payments	<u>\$ 40,836</u>

9. COMMITMENTS AND CONTINGENCES

Litigation Matters

We are not involved in any litigation or other legal proceedings and management is not aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition.

Impact of Coronavirus Pandemic

On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had and are expected to continue to have a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and which the Company's partners operate and conduct their business. We are currently following the recommendations of local health authorities to minimize exposure risk for our team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While we have implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that our continuity plans will be successful.

We have already experienced certain disruptions to our business such as temporary closure of our offices and similar disruptions have occurred for our partners. Specifically, the outbreak has caused temporary shutdowns of the laboratories and other service providers that we rely on to develop our programs, and those laboratories and service providers that have been operating or that have begun operating recently have been doing so with more limited capacity due to social distancing requirements. As a result, our progress has been slowed and there is no assurance that we will be able to meet our previously announced timelines regarding the advancement of our programs.

The extent to which COVID-19 or any other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on our business, results of operations, financial condition and prospects.

10. SEGMENT INFORMATION

We follow the accounting guidance of ASC 280 "Segment Reporting" ("ASC 280"). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer

Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) our legacy Patent Licensing activities. The following represents selected financial information for our segments for the three months ended January 31, 2021 and 2020 and as of January 31, 2021 and October 31, 2020:

	For the Three Months Ended	
	January 31,	
	2021	2020
Net loss:		
CAR-T Therapeutics	\$ (960,736)	\$ (630,333)
Cancer Vaccines	(906,336)	(195,596)
Anti-Viral Therapeutics	(480,806)	-
Cancer Diagnostics	(8,962)	(1,790,646)
Patent Licensing	124,463	-
Total	\$ (2,232,377)	\$ (2,616,575)
Total operating costs and expenses	\$ 2,745,631	\$ 2,629,869
Less non-cash share-based compensation	(986,099)	(1,021,334)
Operating costs and expenses excluding non-cash share-based compensation	\$ 1,759,532	\$ 1,608,535
Operating costs and expenses excluding non-cash share based compensation expense:		
CAR-T Therapeutics	\$ 557,680	\$ 346,341
Cancer Vaccines	537,988	98,270
Anti-Viral Therapeutics	270,256	-
Cancer Diagnostics	6,432	1,163,924
Patent Licensing	387,176	-
Total	\$ 1,759,532	\$ 1,608,535
	January 31,	October 31,
	2021	2020
Total assets:		
CAR-T Therapeutics	\$ 5,849,920	\$ 2,988,124
Cancer Vaccines	5,822,106	946,923
Anti-Viral Therapeutics	2,775,760	2,464,361
Cancer Diagnostics	85,463	2,869,529
Patent Licensing	71,153	184,027
Total	\$ 14,604,402	\$ 9,452,964

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

The Company's consolidated revenue of \$512,500 and inventor royalties, contingent legal fees, litigation and licensing expense of \$385,002 for the three months ended January 31, 2021 were solely related to our patent licensing segment which consists of our encrypted audio/video conference calling technology. All our revenue is generated domestically (United States) based on the country in which the licensee is located.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Information included in this Quarterly Report on Form 10-Q (this "Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual

results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020 and the condensed consolidated financial statements included in this Report. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Report.

GENERAL

We discuss the description of our business in the Notes to our Condensed Consolidated Financial Statements.

RESULTS OF OPERATIONS

Three months ended January 31, 2021 compared with three months ended January 31, 2020

Revenue

For the three months ended January 31, 2021, we recorded revenue of \$512,500 from one license agreement. The license agreement provided for a one-time, non-recurring, lump sum payment in exchange for a non-exclusive retroactive and future license, and covenant not to sue. Pursuant to the terms of the agreement, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Accordingly, the performance obligations from this license agreement were satisfied and 100% of the revenue was recognized upon execution of the license agreement. As discussed in Note 1 to our condensed consolidated financial statements, as part of our legacy operations, the Company remains engaged in limited patent licensing activities which we do not expect to be a significant part of our ongoing operations or revenue.

We had no revenue during the three-month period ended January 31, 2020.

Inventor Royalties, Contingent Legal Fees, Litigation and Licensing Expenses

Inventor royalties, contingent legal fees, litigation and licensing expenses increased to approximately \$385,000 in the three months ended January 31, 2021 from \$0- in the three months ended January 31, 2020. The increase was primarily due to the increase in related revenues. Inventor royalties and contingent legal fees are expensed in the period that the related revenues are recognized. Litigation and licensing expenses related to patent assertion, other than contingent legal fees, are expensed in the period incurred.

Research and Development Expenses

Research and development expenses are related to the development of our cancer therapeutics, vaccine and diagnostics programs and our anti-viral drug program, and decreased by approximately \$663,000 to approximately \$828,000 in the three months ended January 31, 2021, from approximately \$1,491,000 in the three months ended January 31, 2020. The decrease in research and development expenses was primarily due to a decrease in outside research and development expense, excluding license expense, of approximately \$414,000, a decrease in employee compensation and related costs, other than stock option compensation expense, of approximately \$269,000 and a decrease in employee stock option compensation expense of approximately \$105,000, all due to the suspension of development of our cancer diagnostics program, offset by an increase in license fees of approximately \$155,000 primarily related to development of our cancer vaccine technologies.

Research and development expenses incurred in the three months ended January 31, 2021 associated with each of our development programs consisted of approximately \$363,000 for CAR-T therapeutics, approximately \$294,000 for cancer vaccines, approximately \$169,000 for anti-viral therapeutics and approximately \$2,000 for cancer diagnostics.

General and Administrative Expenses

General and administrative expenses increased by approximately \$394,000 to approximately \$1,533,000 in the three months ended January 31, 2021, from approximately \$1,139,000 in the three months ended January 31, 2020. The increase in general and

administrative expenses was primarily due to non-recurring income in the prior year period resulting from the discharge in January 2020 of a disputed liability of approximately \$337,000 upon the expiration of the vendor's statutory right to pursue collection of the disputed liability, an increase in directors compensation of approximately \$81,000, an increase in patent expense of approximately \$76,000 and an increase in consultant stock option and warrant expense of approximately \$56,000, offset by a decrease in employee compensation and related costs, other than stock option compensation expense, of approximately \$148,000.

Interest Income

Interest income decreased by approximately \$12,000 to approximately \$1,000 in the three months ended January 31, 2021, from approximately \$13,000 in the comparable prior year period as a result of a decrease in interest rates.

Net Loss Attributable to Noncontrolling Interest

The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, was approximately \$24,000 and \$24,000, respectively, in the three months ended January 31, 2021 and 2020.

LIQUIDITY AND CAPITAL RESOURCES

Our primary sources of liquidity are cash, cash equivalents and short-term investments.

Based on currently available information as of March 11, 2021, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. During the three months ended January 31, 2021, we raised approximately \$5,957,000, net of expenses, through an at-the-market equity offering of 1,900,547 shares of common stock, under which offering we may issue up to \$50 million of common stock. Under our at-the-market equity program which is currently effective and may remain available for us to use in the future, as of January 31, 2021, we may sell an additional approximately \$34,670,000 of common stock. We may seek to obtain working capital during our fiscal year 2021 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt could result in dilution to our stockholders. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations.

During the three months ended January 31, 2021, cash used in operating activities was approximately \$1,170,000. Cash provided by investing activities was approximately \$675,000, resulting from the proceeds on maturities of certificates of deposit totaling \$1,640,000 and the proceeds from the sale of equipment of approximately \$35,000, which was offset by the purchases of certificates of deposit of approximately \$1,000,000. Cash provided by financing activities was approximately \$6,061,000, resulting from the sale of 1,900,547 shares of common stock in an at-the-market equity offering of approximately \$5,957,000 and the proceeds from exercise of stock options of approximately \$104,000. As a result, our cash, cash equivalents, and short-term investments at January 31, 2021 increased approximately \$4,926,000 to approximately \$13,983,000 from approximately \$9,057,000 at the end of fiscal year 2020.

CRITICAL ACCOUNTING POLICIES

The Company's condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America. In preparing these financial statements, we make assumptions, judgments and estimates that can have a significant impact on amounts reported in our condensed consolidated financial statements. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results

could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly.

We believe that, of the significant accounting policies discussed in Note 2 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020, the following accounting policies require our most difficult, subjective or complex judgments:

Revenue Recognition; and

Stock-Based Compensation

Revenue Recognition

Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive.

We follow the accounting guidance of Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. In accordance with ASC 606 we are required to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time.

Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.

Stock-Based Compensation

The compensation cost for service-based stock options granted to employees, directors and consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is recognized as an expense on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to four years. For employee options vesting if the trading price of the Company’s common stock exceeds certain price targets we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period.

For stock awards granted to employees and directors that vest at date of grant we recognize expense based on the grant date market price of the underlying common stock. For restricted stock awards vesting upon achievement of a price target of our common stock we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest).

The Black-Scholes pricing model and the Monte Carlo Simulation we use to estimate fair value requires valuation assumptions of expected term, expected volatility, risk-free interest rates and expected dividend yield. The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. For employees we use the simplified method, which is a weighted average of the vesting term and contractual term, to determine expected term. The simplified method was adopted since we do not believe that historical experience is representative of future performance because of the impact of the changes in our operations and the change in terms from historical options. For consultants we use the contract term for expected term. Under the Black-Scholes pricing

model, we estimated the expected volatility of our shares of common stock based upon the historical volatility of our share price over a period of time equal to the expected term of the grants. We estimated the risk-free interest rate based on the implied yield available on the applicable grant date of a U.S. Treasury note with a term equal to the expected term of the underlying grants. We made the dividend yield assumption based on our history of not paying dividends and our expectation not to pay dividends in the future.

We will reconsider use of the Black-Scholes pricing model and the Monte Carlo Simulation if additional information becomes available in the future that indicates another model would be more appropriate. If factors change and we employ different assumptions in future periods, the compensation expense that we record may differ significantly from what we have recorded in the current period.

EFFECT OF RECENTLY ISSUED PRONOUNCEMENTS

We do not believe that any of the recently issued accounting pronouncements will have a material effect on the Company's consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As of January 31, 2021, we had investments in short-term, fixed rate and highly liquid instruments that have historically been reinvested when they mature throughout the year. Although our existing instruments are not considered at risk with respect to changes in interest rates or markets for these instruments, our rate of return on these securities could be affected at the time of reinvestment, if any.

Item 4. Controls and Procedures.

We carried out an evaluation, under the supervision and with the participation of our management including our President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13(a)-15(b) of the Exchange Act. Based upon that evaluation, our President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of the end of the period covered by this Report.

There was no change in our internal control over financial reporting during the first quarter of fiscal year 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

We are not involved in any litigation or other legal proceedings and management is not aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition.

Item 1A. Risk Factors.

There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None.

Item 3. Defaults Upon Senior Securities. None.

Item 4. Mine Safety Disclosures. Not Applicable.

Item 5. Other Information. None.

Item 6. Exhibits.

- 10.1 [Amendment to License Agreement between Certainty Therapeutics, Inc. and The Wistar Institute of Anatomy and Biology. \(Certain information has been redacted in the marked portions of the exhibit.\)](#)
- 10.2 [Joint Development and Option Agreement, dated January 26, 2021, between the Company and The Cleveland Clinic Foundation. \(Certain information has been redacted in the marked portions of the exhibit.\)](#)
- 31.1 [Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 11, 2021.](#)
- 31.2 [Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 11, 2021.](#)
- 32.1 [Statement of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 11, 2021.](#)
- 32.2 [Statement of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 11, 2021.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ANIXA BIOSCIENCES, INC.

By: */s/ Dr. Amit Kumar*

Dr. Amit Kumar
Chairman, President and
Chief Executive Officer
(Principal Executive Officer)

March 11, 2021

By: */s/ Michael J. Catelani*

Michael J. Catelani
Chief Operating Officer and
Chief Financial Officer
(Principal Financial and Accounting Officer)

March 11, 2021

Redactions with respect to certain portions hereof denoted with “****”

AMENDMENT OF LICENSE AGREEMENT

This Amendment of License Agreement (this “**Amendment**”) is made as of January 22, 2021 (the “**Amendment Effective Date**”), by and between The Wistar Institute of Anatomy and Biology, a nonprofit corporation organized and existing under the laws of the Commonwealth of Pennsylvania located at 3601 Spruce Street, Philadelphia, Pennsylvania 19104 (“**Wistar**”), and Certainty Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware with principal offices located at 3150 Almaden Expressway, Suite 250, San Jose, California 95118 (“**Company**”).

RECITALS

A. Reference is made to that certain License Agreement dated November 13, 2017 by and between Wistar and Company (the “**Agreement**”). Capitalized terms used but not otherwise defined herein shall have the respective meanings given in the Agreement.

B. Wistar and Company desire to enter into this Amendment for purposes of amending the Agreement as set forth herein.

Now, therefore, in consideration of the premises and mutual covenants contained herein, and intending to be legally bound hereby, the parties hereto agree as follows:

1. Amendment of the Agreement.

(a) Section 1.53 of the Agreement is hereby amended to include the following new sentence at the end of such section:

“Notwithstanding anything to the contrary in this Agreement, the engagement by Company, at any time on or after the Effective Date, of a third party (including Roswell Cancer Center, H. Lee Moffitt Cancer Center or third parties working under the direct supervision of H. Lee Moffitt Cancer Center and/or Company) that authorizes such third party to practice under the Licensed Patents or use Licensed Technical Information solely to perform research or development or other activities for or on behalf of Company on a fee-for-service basis (and without payment to Company of any consideration in the form described under the definition of Non-Royalty Sublicensing Income) shall not be deemed to be a Sublicense for purposes of this Agreement.”

(b) Section 4.2.3 of the Agreement is hereby amended and restated to read in its entirety as follows:

(c) Section 4.2.4 of the Agreement is hereby amended and restated to read in its entirety as follows:

2. Miscellaneous.

(a) Except as expressly amended herein, the Agreement shall remain in full force and effect.

(b) This Amendment shall be construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to conflict of law principles.

(c) This Amendment may be executed in any number of counterparts, each of which shall be deemed an original as against the party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument. Counterpart signatures delivered via facsimile or e-mail in PDF or similar electronic format shall have the same binding effect as original signatures.

(The remainder of this page is intentionally left blank. The signature page follows.)

-2-

In witness whereof, the parties hereto have duly executed this Amendment as of the Amendment Effective Date.

THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

CERTAINTY THERAPEUTICS, INC.

By: /s/ Heather Steinman
Name: Heather Steinman
Title: Vice President for Business
Development & Executive Director,
Technology Transfer
Date: 01/22/2021

By: /s/ Amit Kumar
Name: Amit Kumar
Title: CEO
Date: 1/22/21

-3-

Redactions with respect to certain portions hereof denoted with “****”

Joint Development and Option Agreement

Preamble

This Joint Development and Option Agreement (“**JDA**”), effective and binding as of the last date of execution herein (“**EFFECTIVE DATE**”), is by and between The Cleveland Clinic Foundation (hereinafter referred to along with its **AFFILIATES** as “**CCF**”), an Ohio non-profit corporation with offices located at 9500 Euclid Avenue, Cleveland, Ohio 44195; and Anixa Biosciences, Inc. (hereinafter referred to as “**COMPANY**”), a Delaware corporation having its principal office at 3150 Almaden Exp., Suite 250, San Jose, CA 95118.

Background

WHEREAS, the **PARTIES** have an interest in working together to develop vaccines for the prevention and treatment of ovarian cancer.

WHEREAS, the project contemplated hereby is of mutual interest and benefit to **CCF** and **COMPANY** and will be consistent with the objectives of both **PARTIES** in a manner consistent with the status of **CCF** as a nonprofit institution.

NOW THEREFORE, in consideration of the mutual covenants and promises herein made, **CCF** and **COMPANY** agree as follows:

Agreement

1. Definitions

- 1.1. “**AFFILIATE**” means any corporation, association or other entity that directly or indirectly controls, is controlled by, or is under common control with the **PARTY** in question. As used in this definition, the term “control” means direct or indirect beneficial ownership of more than 50% of the voting or equity interest in such corporation or other business entity.
- 1.2. “**BACKGROUND IP**” means the **CCF BACKGROUND IP** or the **COMPANY BACKGROUND IP**, as the case may be.
- 1.3. “**COLLABORATION FIELD**” means vaccines for the prevention or treatment of ovarian cancer and other cancers which express the Anti-Mullerian Hormone Receptor 2 (**AMHR2**) protein, including an Anti-Mullerian Hormone Receptor 2 protein with an extracellular domain (**AMHR2-ED**), corresponding adjuvants and any companion diagnostics.
- 1.4. “**CCF**” is defined in the Preamble.
- 1.5. “**CCF BACKGROUND IP**” means any **IP** first conceived, developed, reduced to practice, acquired and/or otherwise controlled by **CCF** or its **AFFILIATES** either (i) prior to the **EFFECTIVE DATE** or (ii) outside of the scope of this **JDA** and during the **TERM** of this **JDA**, including rights arising in the course of prosecution and maintenance of such **IP**.
- 1.6. “**CCF INVENTIONS**” is defined in Paragraph 5.2.2.
- 1.7. “**CCF PROJECT TEAM**” shall mean the following individuals: Vince Tuohy, Justin Johnson, Chhavi Jain and Suparna Mazumder.
- 1.8. “**CLINICAL TRIALS**” is defined in Paragraph 2.6.
- 1.9. “**COMPANY BACKGROUND IP**” means any **IP** first conceived, developed, reduced to practice, acquired, and/or otherwise controlled by **COMPANY** or its **AFFILIATES** either (i) prior to the **EFFECTIVE DATE** or (ii) outside of the scope of this **JDA** and during the **TERM** of this **JDA**, including rights arising in the course of prosecution and maintenance of such **IP**.

1.10. “COMPANY INVENTIONS” is defined in Paragraph 5.2.1.

1.11. “CONFIDENTIAL INFORMATION” means all non-public, confidential or proprietary information of a PARTY, or its AFFILIATES or REPRESENTATIVES, that is disclosed directly or indirectly from or on behalf of the DISCLOSING PARTY to the RECEIVING PARTY, whether in oral, written, electronic or other form or media, whether or not such information is marked, designated or otherwise identified as “confidential” and that, due to the nature of its subject matter or circumstances surrounding its disclosure, would reasonably be understood to be confidential or proprietary, including, without limitation, the terms and existence of this JDA.

CONFIDENTIAL INFORMATION does not include information that the RECEIVING PARTY can demonstrate by documentation or other evidence (i) was already known to the RECEIVING PARTY without restriction on use or disclosure prior to the receipt of such information directly or indirectly from or on behalf of the DISCLOSING PARTY; (ii) was independently developed by the RECEIVING PARTY without use of or reference to the DISCLOSING PARTY’s CONFIDENTIAL INFORMATION; (iii) is or becomes generally known to the public or otherwise becomes publicly available, other than through a breach of this JDA or the License Agreement by the RECEIVING PARTY; or (iv) is or was made available to the RECEIVING PARTY on a non-confidential basis by a THIRD PARTY having the lawful right to do so without breaching any obligation of confidentiality to the DISCLOSING PARTY.

1.12. “DISPUTE” is defined in Paragraph 9.1.

1.13. “EFFECTIVE DATE” is defined in the Preamble.

1.14. “INTELLECTUAL PROPERTY” is also referred to as “IP” and means any rights in INVENTIONS, patents, trademarks, copyrights or any other proprietary rights relating to intangible property anywhere in the world, and all registrations and applications related to any of the foregoing and analogous rights thereto anywhere in the world.

1.15. “INVENTION” means any creative or technical idea, design, development, discovery, drawing, data, analysis, trade secret, technology, process or method, know-how, material composition, article of manufacture, machine, or work result, including business and marketing plans, prototypes, specifications, developed or discovered in performing the PROJECT, whether or not patentable.

1.16. “JDA” means this Joint Development and Option Agreement, as amended from time to time.

1.17. “JOINT INVENTIONS” is defined in Paragraph 5.2.3.

1.18. “LICENSE AGREEMENT” means that certain Exclusive License Agreement between the PARTIES dated October 20, 2020.

1.19. “LOSSES” means all losses, damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys’ fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers.

1.20. “OPTION PERIOD” is defined in Paragraph 6.2.1.

1.21. “PARTY” means either CCF or COMPANY, and “PARTIES” means the two collectively.

1.22. “PATENT RIGHTS” means foreign and domestic patent and/or design application(s), including continuations, continuations-in-part, divisionals, reissues, reexaminations, extensions and renewals thereof, and patents/registrations issuing therefrom.

- 1.23. “**PRODUCT**” means any embodiment of an INVENTION. PRODUCT may take the form of, but shall not be limited to, a formula, description or performance of a process, device, software program, or service.
- 1.24. “**PROJECT**” is defined in Paragraph 2.1.
- 1.25. “**PROSECUTION**” means preparing, filing, prosecuting, and/or maintaining a subject patent application(s) and/or patent(s).
- 1.26. “**TECHNICAL REPRESENTATIVE**” is defined in Paragraph 2.3.
- 1.27. “**TERM**” is defined in Paragraph 8.1.
- 1.28. “**THIRD PARTY**” or “**THIRD PARTIES**” means any individual(s), corporation(s), association(s), government agencies, or other entity(ies), which is/are not a PARTY or any of its AFFILIATES.
- 1.29. “**WORK PLAN**” is defined in Paragraph 2.1.

2. Collaborative Project

- PROJECT.** The PARTIES will collaborate in efforts (undertaken jointly and individually) that are intended to result in the development of one or more products in the COLLABORATION FIELD as set forth in this JDA (such efforts referred to as the “**PROJECT**”). Particular goals of the PROJECT will be defined generally by the schedule of activities, responsibilities, milestones, and objectives (“**WORK PLAN**”), which shall be set forth in Schedule A, attached hereto and incorporated herein. The PARTIES will review and may update the WORK PLAN by mutual agreement from time to time, provided that any amendment to the WORK PLAN made subsequent to the execution of this JDA shall be signed by both PARTIES in accordance with Paragraph 11.4.
- 2.1.

- Project Performance.** Each PARTY will promptly undertake performance of the PROJECT. During the TERM of the JDA, the PARTIES will endeavor to perform their respective duties and to develop and submit to each other any deliverables identified in the WORK PLAN using reasonable efforts. COMPANY acknowledges and agrees that the PROJECT is a research project and successful completion of the research is not assured. Each PARTY acknowledges and agrees that as long as the other PARTY uses its reasonable efforts to perform its obligations under this JDA, including the WORK PLAN, such other PARTY shall not be in default under this JDA for any failure to achieve any particular result or deliverable. Each PARTY will ensure that its respective employees, contractors, and students who perform the PROJECT (including the CCF PROJECT TEAM) and/or have access to the CONFIDENTIAL INFORMATION of the other PARTY (a) are bound by written non-disclosure and non-use agreements at least as restrictive as those set forth in Article 4 and (b) are contractually obligated to assign and transfer to such PARTY all right, title and interest to the INVENTIONS and all IP therein.
- 2.2.

- Technical Representative.** Each PARTY will designate two of the PARTY’s employees as the principal technical representatives (“**TECHNICAL REPRESENTATIVE**”) for consultation and communications between the PARTIES. A PARTY may change a TECHNICAL REPRESENTATIVE at any time, upon written notice to the other PARTY.
- 2.3.

- Reports.** The TECHNICAL REPRESENTATIVES will be reasonably available by telephone, e-mail, or in person to discuss the progress and results, as well as ongoing plans, or changes therein, of the work under the PROJECT.
- 2.4.

- Funding.** Except as specifically provided to the contrary in this JDA, all costs, fees and/or expenses incurred in connection with this JDA will be paid by the PARTY incurring such costs, fees and/or expenses.
- 2.5.

Redactions with respect to certain portions hereof denoted with “***”

- Human Clinical Trials:** If the PARTIES identify a need for which COMPANY desires to engage CCF to perform and/or coordinate research with human subjects (“**CLINICAL TRIALS**”), then the PARTIES will execute a clinical trial agreement to govern the CLINICAL TRIALS prior to proceeding.
- 2.6.

Non-Employee Access. COMPANY, and its personnel, employees, or agents (“COMPANY STAFF”) may visit CCF’s facilities and interact with CCF’s employees only if such participation is explicitly provided for in Schedule A. Such visitations and interactions shall be at mutually agreed upon times, during normal business hours and subject to COMPANY STAFF’s compliance with CCF’s policies and credentialing procedures for non-employee access to its facilities, patients, and/or records. COMPANY STAFF will at all times be under COMPANY’s direction and control and will not be deemed employees of CCF. COMPANY shall ensure that COMPANY STAFF are covered by general liability, worker’s compensation and unemployment insurance and will discharge all other obligations of an employer as applicable. Use of or access to any CCF facilities, equipment or materials (collectively “CCF Resources”) by COMPANY STAFF shall be at COMPANY’s sole risk and only with the prior written approval of the CCF PROJECT TEAM. COMPANY shall be solely liable for any damages, loss or harm caused by COMPANY STAFF while on CCF property, provided COMPANY shall not be liable to the extent such damage, loss or harm is directly attributable to the negligence or willful misconduct of CCF or CCF’s personnel. Use of or access by COMPANY STAFF cannot conflict with use required by CCF patients or CCF personnel (who shall always have first priority of use). There will be no use of radioactive materials by COMPANY STAFF. Restricted materials may be used or accessed only with the express written agreement of the CCF PROJECT TEAM and only under conditions that fully comply with CCF regulations and licenses, including full disclosure to CCF’s Facility Safety Officials. CCF shall not be liable for failure or interruption of utilities, equipment or other CCF Resources in connection with COMPANY’s access rights under this Paragraph 2.7. No COMPANY STAFF shall have any supervisory right or authority over any employee, agent or student of CCF. While on CCF’s campus and/or using CCF Resources, COMPANY STAFF shall abide by all applicable laws and CCF policies and procedures.

2.7.

3. Payments

- 3.1. **Option Fee.** COMPANY will pay CCF a non-refundable, option fee totaling \$*** payable within *** of the EFFECTIVE DATE.
- 3.2. **Development Funding.** COMPANY will provide USD\$*** in development funding. The first payment of \$*** shall be paid within *** of the EFFECTIVE DATE, and the remaining \$*** shall be paid on ***.
- 3.3. **Time is of the essence with respect to this payment. All payments shall be due and payable in U.S. dollars. Any past due amounts shall accrue interest at an annual rate equal to ***.**

4. Confidentiality

- 4.1. **Confidentiality Obligations.** Each PARTY (the “RECEIVING PARTY”) acknowledges that in connection with this JDA it will gain access to CONFIDENTIAL INFORMATION of the other PARTY (the “DISCLOSING PARTY”). As a condition to being provided with CONFIDENTIAL INFORMATION, the RECEIVING PARTY shall:
- 4.1.1. not use the DISCLOSING PARTY’s CONFIDENTIAL INFORMATION other than as necessary to exercise its rights and perform its obligations under this JDA or the License Agreement; and
- 4.1.2. maintain the DISCLOSING PARTY’s CONFIDENTIAL INFORMATION in strict confidence and, subject to Paragraph 4.2, not disclose the DISCLOSING PARTY’s CONFIDENTIAL INFORMATION without the DISCLOSING PARTY’s prior written consent, provided, however, the RECEIVING PARTY may disclose the CONFIDENTIAL INFORMATION to its employees, officers, directors, consultants and legal advisors (“REPRESENTATIVES”) who:

Redactions with respect to certain portions hereof denoted with “***”

- 4.1.2.1. have a need to know the CONFIDENTIAL INFORMATION for purposes of the RECEIVING PARTY’s performance, or exercise of its rights concerning the CONFIDENTIAL INFORMATION, under this JDA or the License Agreement;
- 4.1.2.2. have been apprised of this restriction; and

- are themselves bound by written non-disclosure and non-use agreements at least as restrictive as those set forth in this Paragraph 4.1, provided further that the RECEIVING PARTY shall be responsible for ensuring its REPRESENTATIVES' compliance with, and shall be liable for any breach by its REPRESENTATIVES of, this Paragraph 4.1.
- 4.1.2.3.

The RECEIVING PARTY shall use reasonable care, at least as protective as the efforts it uses for its own confidential information, to safeguard the DISCLOSING PARTY'S CONFIDENTIAL INFORMATION from use or disclosure other than as permitted hereby.

- 4.2. **Exceptions.** If the RECEIVING PARTY becomes legally compelled to disclose any CONFIDENTIAL INFORMATION, the RECEIVING PARTY shall:

4.2.1. provide prompt written notice to the DISCLOSING PARTY so that the DISCLOSING PARTY may seek a protective order or other appropriate remedy or waive its rights pursuant to Paragraph 11.12; and

4.2.2. disclose only the portion of CONFIDENTIAL INFORMATION that it is legally required to furnish.

If a protective order or other remedy is not obtained, or the DISCLOSING PARTY waives compliance in accordance with Paragraphs 11.10 and 11.12, the RECEIVING PARTY shall, at the DISCLOSING PARTY'S expense, use reasonable efforts to obtain assurance that confidential treatment will be afforded the CONFIDENTIAL INFORMATION.

- 4.3. **Confidential Terms.** Notwithstanding anything to the contrary herein, the PARTIES may disclose the terms and existence of this JDA to potential or actual investors, acquirers, sublicensees, collaboration partners, consultants, advisors and others on a reasonable need to know basis subject to customary confidentiality restrictions, or as required by securities or other applicable laws.

- 4.4. **Scientific Publications.** COMPANY recognizes and accepts the importance of communicating medical study and scientific data and the necessity of conveying such information in a timely manner, and, therefore, encourages their publication in reputable scientific journals and at seminars or conferences. COMPANY further recognizes and accepts that under CCF's mission as an academic medical center, CCF and its investigators must have a meaningful right to publish without COMPANY'S approval or editorial control; provided that CCF shall comply with the requirements in this Paragraph 4.4. CCF shall submit to COMPANY for its review a copy of any proposed manuscript *** prior to the estimated date of submission for publication. Within *** of receiving such manuscript (the "REVIEW PERIOD"), if COMPANY reasonably determines that the proposed publication contains patentable subject matter which requires protection for COMPANY, COMPANY may require the delay of publication for a period of time not to exceed *** for the purpose of filing patent applications. Further, CCF and its investigators agree to remove from the proposed publication anything that COMPANY identifies within the REVIEW PERIOD as COMPANY'S CONFIDENTIAL INFORMATION. If no written response is received from COMPANY within the REVIEW PERIOD, it may be conclusively presumed that publication may proceed without delay. For avoidance of any doubt, CCF and the CCF PROJECT TEAM (while employees of CCF) retain the right to publish any medical study or scientific data arising from the PERMITTED RESEARCH (as defined in Paragraph 6.4), subject to compliance with this Paragraph 4.4.

Redactions with respect to certain portions hereof denoted with "****"

5. INVENTION Rights

- 5.1. **BACKGROUND IP.** Each PARTY'S BACKGROUND IP will remain the absolute unencumbered property of the respective PARTY. Except for the limited rights explicitly set forth in Paragraph 5.8 (Right to Use BACKGROUND IP & INVENTIONS), this JDA does not confer any rights under the BACKGROUND IP of either PARTY.

- 5.2. **INVENTION Rights.** INVENTIONS will be owned as follows:

5.2.1. **COMPANY INVENTIONS.** All INVENTIONS made solely by COMPANY employees or contractors in performance of the PROJECT and during the TERM and OPTION PERIOD together with all IP therein will, as between COMPANY and CCF, be owned solely by COMPANY ("COMPANY INVENTIONS").

5.2.2. CCF INVENTIONS. All INVENTIONS made solely by CCF employees, contractors or students in performance of the PROJECT and during the TERM and OPTION PERIOD together with all IP therein will, as between COMPANY and CCF, be owned solely by CCF (“**CCF INVENTIONS**”).

5.2.3. JOINT INVENTIONS. All INVENTIONS made jointly by COMPANY employees or contractors and by CCF employees, contractors or students in performance of the PROJECT and during the TERM and OPTION PERIOD, in each case together with all IP therein, will be jointly owned by COMPANY and CCF (“**JOINT INVENTIONS**”). Subject to the rights and licenses granted under this JDA and the License Agreement, with respect to JOINT INVENTIONS, each PARTY hereby confirms that nothing in this JDA shall operate in any way to limit the other PARTY’s indivisible, non-exclusive ownership interest in and to such JOINT INVENTIONS, including the right to use and exploit the JOINT INVENTIONS for all purposes on a worldwide basis, without consent of and without a duty of accounting to the other PARTY.

5.2.4. Cooperation in Transferring Title. The PARTIES will cooperate fully with each other and/or the other PARTY’s attorneys in vesting title as provided in Article 5 (INVENTION Rights), including executing documents as necessary to effectuate the intent of the foregoing.

5.3. Notification of INVENTION. Each PARTY will provide the other PARTY with timely notification in writing of each INVENTION developed solely or jointly by such PARTY (“**INVENTION DISCLOSURE**”).

5.4. PROSECUTION of Patent Applications. During the TERM and the applicable OPTION PERIOD, CCF will have the exclusive responsibility to conduct PROSECUTION and enforcement of PATENT RIGHTS within the CCF INVENTIONS and JOINT INVENTIONS at CCF’s sole discretion (but using patent counsel reasonably acceptable to COMPANY), subject to Paragraph 5.6 (Abandonment), and COMPANY will be responsible for all documented, out-of-pocket costs associated with such PROSECUTION. CCF will keep COMPANY informed of such PROSECUTION, consider COMPANY’s comments and suggestions prior to taking material actions for the same, and consider actions reasonably recommended which would expand the scope of rights sought. COMPANY will provide written communication of items of commercial interest and CCF will cooperate to insure that the PROSECUTION of each CCF INVENTION and JOINT INVENTION reflects, and will reflect, to the extent practicable, these items of commercial interest. Final decisions on PROSECUTION of CCF INVENTIONS and JOINT INVENTIONS will be at CCF’s sole discretion, subject to Paragraph 5.6 (Abandonment). If COMPANY does not exercise the OPTION with respect to a particular CCF INVENTION or JOINT INVENTION during the corresponding OPTION PERIOD, then (i) in the case of a CCF INVENTION, COMPANY will thereafter no longer be responsible for any costs associated with PROSECUTION of PATENT RIGHTS within such CCF INVENTION, and (ii) in the case of a JOINT INVENTION, the PARTIES will discuss in good faith and mutually agree in writing as to which PARTY will have responsibility to conduct further PROSECUTION and enforcement of PATENT RIGHTS within such JOINT INVENTION, including the allocation of the costs and any recoveries associated with such PROSECUTION and enforcement.

Redactions with respect to certain portions hereof denoted with “***”

5.5. Review of Patent Applications Prior to Filing. A PARTY will not file any patent application that discloses CONFIDENTIAL INFORMATION of the other PARTY and/or claims an INVENTION without prior notice to, and review by, the other PARTY. The reviewing PARTY will be given at least *** in which to review and comment on the patent application, unless the reviewing PARTY agrees on a term which is shorter than ***. The reviewing PARTY will have the right to require that any CONFIDENTIAL INFORMATION of the reviewing PARTY be removed from the patent application, in accordance with Article 4 (Confidentiality); with the limited exception that those portions of CONFIDENTIAL INFORMATION that are INVENTIONS owned by either PARTY pursuant to Article 5 (INVENTION Rights) and are required to be disclosed by the filing PARTY in the subject patent application to secure PATENT RIGHTS to which the filing PARTY is entitled under this JDA, may remain in the patent application.

5.5.1. Review of OFFICE ACTIONS. CCF will instruct its outside counsel to provide to COMPANY or its designated patent counsel copies of all materially relevant correspondence to and from the U.S. Patent and Trademark Office, and all correspondence related to counterpart foreign patent applications, including correspondence from foreign

associates and from government agencies, in connection with CCF's PROSECUTION of PATENT RIGHTS under this Article 5.

Abandonment. Notwithstanding Paragraph 5.4 (PROSECUTION of Patent Applications), CCF may elect to abandon PROSECUTION at any time, including prior to beginning PROSECUTION. If CCF chooses to abandon or not to begin PROSECUTION, then CCF will provide COMPANY at least *** prior written notice of such intended abandonment and the right to assume PROSECUTION of the PATENT RIGHTS that were to be abandoned. If COMPANY elects to assume PROSECUTION of such PATENT RIGHTS, then COMPANY will be responsible for all subsequent costs associated with the PROSECUTION of the subject PATENT RIGHTS; and CCF will assign the subject PATENT RIGHTS to COMPANY.

- 5.6. Following any such assignment, during the TERM and the applicable OPTION PERIOD, to the extent necessary to carry out the PROJECT, COMPANY grants to CCF a worldwide, royalty-free, non-exclusive, license, without the right to sublicense, to practice the subject PATENT RIGHTS. CCF will use best efforts not to abandon patents of interest to COMPANY. If, within *** of providing such written notice of intended abandonment, CCF does not receive written notice from COMPANY electing to assume PROSECUTION, CCF may subsequently proceed with abandonment of the subject PATENT RIGHTS at its discretion. Failure to exercise commercially reasonable efforts to enforce PATENT RIGHTS shall be deemed abandonment thereof under this Paragraph.

PROSECUTION in Countries Not Elected by CCF. If COMPANY desires to file a patent application in countries other than those CCF desires to file in, then the subject PATENT RIGHTS (for such country) shall be deemed intended to be abandoned by CCF, and therefore treated as such under Paragraph 5.6 (Abandonment). COMPANY will be free to file such patent applications in the desired other countries at its own expense; and CCF will assign the subject PATENT RIGHTS for such country to COMPANY. Concurrent with CCF's assignment of the patent application to COMPANY, COMPANY grants CCF during the TERM and OPTION PERIOD, to the extent necessary to carry out the PROJECT, a worldwide, royalty-free, non-exclusive, license, without the right to sublicense, to practice the subject PATENT RIGHTS.

- 5.7.

Redactions with respect to certain portions hereof denoted with “***”

5.8. **Right to Use BACKGROUND IP & INVENTIONS.**

5.8.1. **During the TERM and OPTION PERIOD.** The PARTIES shall have the following license rights.

5.8.1.1. **CCFs Rights.** During the TERM and OPTION PERIOD, to the extent necessary to carry out the PROJECT, COMPANY grants CCF a non-exclusive, royalty-free, non-transferable, worldwide license without the right to sublicense to practice COMPANY BACKGROUND IP and COMPANY INVENTIONS.

5.8.1.2. **COMPANY's Rights.** During the TERM and OPTION PERIOD, to the extent necessary to carry out the PROJECT, CCF grants COMPANY a non-exclusive, royalty-free, non-transferable, worldwide license without the right to sublicense to practice CCF BACKGROUND IP and CCF INVENTIONS.

- 5.9. **No Implied Rights.** Except as expressly set forth herein, neither COMPANY nor CCF transfers to the other PARTY, by operation of this JDA, rights to any patent, copyright, trademark, or other IP of any kind.

6. **Option to License**

- 6.1. **Option Grant.** CCF grants COMPANY an exclusive option to take a license under certain IP of CCF in the COLLABORATION FIELD, as follows (“OPTION”):

6.1.1. **Option for Patent License.** CCF grants COMPANY an exclusive option to obtain an exclusive, royalty-bearing, worldwide license, with the right to sublicense, subject to the terms and conditions of the License Agreement, under any PATENT RIGHTS within the CCF INVENTION or JOINT INVENTION.

6.1.2. **Exercise of OPTION.** On a CCF INVENTION-by-CCF INVENTION and JOINT INVENTION-by-JOINT INVENTION basis, COMPANY may exercise the OPTION with respect to the PATENT RIGHTS claiming the applicable INVENTION anytime during the the OPTION PERIOD with respect to such INVENTION by

providing CCF written notice specifically declaring COMPANY's intent to exercise the OPTION. Upon providing such notice, all PATENT RIGHTS claiming the applicable INVENTION are hereby automatically deemed to be Licensed Patents under, and subject to the terms and conditions of, the License Agreement, and the definition of Licensed Patents thereunder is hereby automatically deemed to be amended to include such PATENT RIGHTS, without any further action by either PARTY. For clarity, in such event, the PROSECUTION and enforcement of such PATENT RIGHTS will thereafter be governed by the terms and conditions of the License Agreement (and no longer by Article 5 of this JDA).

- 6.1.3. **Exclusive Option.** The OPTION is exclusive in that during the applicable OPTION PERIOD, CCF will neither enter into a transaction nor negotiate with a THIRD PARTY for access to the applicable CCF INVENTION or JOINT INVENTION, or the underlying INTELLECTUAL PROPERTY (subject only to a reservation of rights for CCF to practice the subject INTELLECTUAL PROPERTY as described below in Paragraph 6.4).

6.2. Option Period

- 6.2.1. **Initial Option Period.** With respect to each CCF INVENTION and JOINT INVENTION, the OPTION will remain in effect from COMPANY's receipt of the corresponding INVENTION DISCLOSURE until the earlier of *** after the expiration of the TERM of the JDA or until the OPTION is exercised under Paragraph 6.1.2 (Exercise of OPTION) ("**OPTION PERIOD**") unless terminated earlier under Paragraph 8.2 (Expiration/Termination of JDA and OPTION).

Redactions with respect to certain portions hereof denoted with "****"

- 6.2.2. **Extending the Option Period.** The OPTION PERIOD may be extended by any extension of this JDA or any other agreement between the PARTIES.

- 6.2.3. **DILIGENCE.** At all times during the applicable OPTION PERIOD, COMPANY will exercise commercially reasonable diligence to determine if COMPANY desires to exercise the applicable OPTION ("**DILIGENCE EFFORTS**"). At the request of CCF but not more often than biannually, COMPANY agrees to report its DILIGENCE EFFORTS to CCF, and any such report will be deemed to be COMPANY's CONFIDENTIAL INFORMATION. If CCF determines that COMPANY is failing to perform reasonable DILIGENCE EFFORTS and notifies COMPANY to such effect in writing, the TECHNICAL REPRESENTATIVES shall work together to identify and agree upon reasonable development milestones which will thereafter constitute reasonable DILIGENCE EFFORTS. Thereafter, if COMPANY fails to perform such reasonable DILIGENCE EFFORTS during the OPTION PERIOD, CCF may elect to terminate the applicable OPTION upon written notice to COMPANY as CCF's sole and exclusive remedy for COMPANY's failure to perform such DILIGENCE EFFORTS.

- 6.3. **Other Subject Matter.** All unpatentable or unpatented subject matter within CCF INVENTIONS and JOINT INVENTIONS (including, for the avoidance of doubt, unpatentable or unpatented data and know-how) are hereby automatically deemed to be Licensed Know-how under, and subject to the terms and conditions of, the License Agreement and the definition of Licensed Know-how thereunder is hereby automatically deemed to be amended to include all such subject matter, without any further action by either PARTY.

- 6.4. **Reservation of Rights for CCF.** Upon exercise of the OPTION with respect to any CCF INVENTION or JOINT INVENTION, any and all licenses granted pursuant to the License Agreement under the corresponding Licensed Patent(s) (as defined in the License Agreement) are subject to the right of CCF, on behalf of itself and its investigators, to practice and use such Licensed Patents and the subject matter described and/or claimed therein, and to permit others at academic, government, and not-for-profit institutions to practice and use such Licensed Patents and the subject matter described and/or claimed therein, for its and their own research (including without limitation, pre-clinical, non-clinical and clinical research), testing, educational, internal or patient-care purposes. For avoidance of any doubt, any research previously performed, currently being performed, or performed in the future by CCF, at CCF's facilities or using CCF's resources, or that CCF or the CCF PROJECT TEAM is in any way related to (whether as Principal Investigator, sponsor or otherwise) is subject to the retained rights in this Paragraph 6.4 (the "**PERMITTED RESEARCH**"). PERMITTED RESEARCH includes, without limitation, any research activities of CCF or the CCF PROJECT TEAM (while employees of CCF) that are funded in whole

or in part by any governmental authorities or any philanthropic or similar sources. For clarity, CCF agrees and acknowledges that this Paragraph 6.4 does not give CCF the right to practice or use the Licensed Technology (as defined in the License Agreement) in connection with the commercial sale of any product or service.

6.5. Licensed Patent Challenges. Upon exercise of the OPTION with respect to any CCF INVENTION or JOINT INVENTION, COMPANY will be subject to the restrictions on Licensed Patent Challenges (as defined in the License Agreement) with respect to the corresponding Licensed Patent(s) (as defined in the License Agreement).

6.6. No License Agreement. If this JDA expires without exercise by COMPANY of any OPTION pursuant to Paragraph 6.1.2 and CCF has complied with all of its obligations under Paragraphs 6.1 and 6.2, COMPANY will grant to CCF a non-exclusive, non-sublicenseable, non-transferable, royalty-free, worldwide license to practice COMPANY INVENTIONS solely for the purpose of CCF's own research and, for clarity, not in connection with the commercial sale of any product or service.

Redactions with respect to certain portions hereof denoted with “***”

7. Work with THIRD PARTIES

7.1. Work with THIRD PARTIES. Neither COMPANY nor CCF will, during the TERM, subcontract any portion of its responsibilities under this JDA or the WORK PLAN to any THIRD PARTY without the prior written consent of the other PARTY. Either PARTY is otherwise free to enter into other collaborative and/or service projects with THIRD PARTIES, provided that the confidentiality and invention rights provisions of Articles 4 and 5 hereof are not breached thereby and such arrangements do not otherwise conflict with the terms and conditions of this JDA. Each PARTY is responsible for the acts and omissions of its permitted subcontractors, including any breach of this JDA.

8. Term and Termination

8.1. Term. This JDA is effective from the EFFECTIVE DATE and terminates upon the later of (i) *** thereafter and (ii) completion by CCF of its activities under the WORK PLAN, unless terminated earlier under Paragraph 8.2 (Expiration/Termination of JDA and OPTION) (“**TERM**”).

8.2. Expiration / Termination of JDA and OPTION.

COMPANY may terminate this JDA at any time for any reason by giving written notice to CCF at least *** before such termination becomes effective. CCF may terminate this JDA if circumstances beyond its control preclude continuation of the PROJECT by giving written notice to COMPANY at least *** before such termination becomes effective.

8.2.1. COMPANY may terminate any OPTION at any time for any reason by giving written notice to CCF. Upon termination of this JDA by COMPANY under this Paragraph 8.2.1, CCF will be reimbursed by COMPANY for all costs and non-cancelable commitments incurred by CCF in the performance of the PROJECT for which COMPANY has committed to fund.

In the event that either PARTY (“**Breach Party**”) shall commit any material breach of or default in any of the terms or conditions of this JDA, the other PARTY may provide written notice (“**Breach Notice**”) of such breach or default to the Breach Party. If the Breach Party fails to remedy said default or breach within *** after receipt of the Breach Notice, the other PARTY may terminate this JDA by sending written notice of termination (“**Termination Notice**”) to the Breach Party to such effect, and such termination shall be effective as of the date of receipt of the Termination Notice.

8.2.2.

If Vince Tuohy becomes unavailable to oversee and support the performance of the WORK PLAN for any reason, CCF may propose another member of its faculty who is acceptable to COMPANY, in COMPANY's sole discretion, to oversee the performance of the WORK PLAN. If a substitute faculty member acceptable to COMPANY has not been agreed upon within *** after Vince Tuohy is no longer available to oversee and support the performance of the WORK PLAN, either PARTY may terminate this JDA upon written notice thereof to the other PARTY.

8.2.3.

8.3. **Tax Exempt Status.** The PARTIES recognize that CCF is a non-profit, tax-exempt organization and agree that this JDA will take into account and be consistent with CCF's tax-exempt status. If any part or all of this JDA is determined to jeopardize the overall tax-exempt status of CCF and/or any of its tax-exempt AFFILIATES, the PARTIES will negotiate in good faith an amendment of this JDA pursuant to Paragraph 11.13 so as to address such tax consideration while effecting the original intent of the PARTIES as closely as possible in a mutually acceptable manner. If the PARTIES are unable to amend the JDA to address such tax consideration within *** after COMPANY's receipt of written notice that the JDA jeopardizes the overall tax-exempt status of CCF, CCF shall have the right to terminate the JDA immediately upon written notice to COMPANY.

Redactions with respect to certain portions hereof denoted with “***”

8.4. **Surviving Rights & Obligations.** Except as expressly provided for herein, termination or expiration of this JDA will not relieve either PARTY of any obligations accruing prior to such termination or expiration, and the following provisions will survive any expiration or termination of this JDA and remain in effect: Articles 4 (Confidentiality), 5 (INVENTION Rights) (excluding Paragraph 5.8), 9 (Dispute Resolution) and 11 (Miscellaneous) and Paragraphs 8.4 (Surviving Rights & Obligations), 10.5 (Liability), 10.6 (Indemnity), 10.7 (DISCLAIMER OF WARRANTIES BY CCF), and 10.8 (DISCLAIMER OF WARRANTIES BY COMPANY). In addition, the OPTION with respect to each CCF INVENTION and JOINT INVENTION will survive any expiration or termination of this JDA for the duration of the applicable OPTION PERIOD, unless so terminated as provided for under Paragraphs 6.2.3 and 8.2.1.

9. Dispute Resolution

9.1. **Exclusive Dispute Resolution Mechanism.** The PARTIES shall resolve any dispute, controversy or claim arising out of or relating to this JDA, or the breach, termination or invalidity hereof (each, a “DISPUTE”), under the provisions of this Article 9. The procedures set forth in this Article 9 shall be the exclusive mechanism for resolving any DISPUTE that may arise from time to time, subject to Paragraph 9.5.

9.2. **Good Faith Negotiations.** If a PARTY believes that a DISPUTE exists, then such PARTY (the “DECLARING PARTY”) shall provide notice of such DISPUTE to the other PARTY (the “NOTICE”), which NOTICE shall specify the nature and cause of the DISPUTE and the action that the DECLARING PARTY deems necessary to resolve such DISPUTE. Following receipt of the NOTICE, the PARTIES shall use good faith efforts to resolve the DISPUTE, including making personnel with appropriate decision-making authority available to the other PARTY to discuss resolution of the DISPUTE. If a DISPUTE is not resolved within *** of the date of the non-DECLARING PARTY's receipt of the NOTICE, then the DISPUTE shall be submitted to mandatory, final and binding arbitration before the American Arbitration Association, in accordance with the then-current rules of the American Arbitration Association, as modified herein.

9.3. **Arbitration.** The PARTIES shall use a panel of three arbitrators. The DECLARING PARTY shall select one arbitrator, and the other PARTY shall select a second arbitrator, and the two arbitrators so selected shall select a third arbitrator. The three arbitrators shall hear the DISPUTE. Such arbitrators shall be knowledgeable in intellectual property law and related matters. The arbitrators shall make each determination in a manner that is consistent with this JDA, including the PARTIES' intent as expressed herein. Without limiting the foregoing, the PARTIES agree that the arbitrators are empowered to make determinations regarding the reasonableness of a PARTY's acts or omissions. All decisions of the arbitrators shall be binding upon the PARTIES. Each PARTY shall be solely responsible for its own attorneys' fees and expenses, legal expenses and witness fees and expenses. Any other usual and customary expenses incurred by the arbitrators or the expense of such arbitration proceeding shall be equally divided between the PARTIES, irrespective of the outcome of such proceeding. The arbitration will be conducted in Cleveland, Ohio. The arbitrators are to apply the laws of the State of Ohio, without regard to its conflict of laws' provisions. The PARTIES agree that any award, order, or judgment pursuant to the arbitration is final and may be entered and enforced in any court of competent jurisdiction. The PARTIES agree that all aspects of the dispute resolution process, including the arbitration, shall be conducted in confidence. The PARTIES agree that all statements made in connection with informal dispute resolution efforts shall not be considered admissions or statements against interest by any PARTY. The PARTIES further agree that they will not attempt to introduce such statements at any later trial, arbitration or mediation between the PARTIES.

9.4. **Waiver of Jury Trial.** Each PARTY irrevocably and unconditionally waives any right it may have to a trial by jury for any legal action arising out of or relating to this JDA or the transactions contemplated hereby.

- Equitable Relief.** Notwithstanding anything to the contrary herein, each PARTY acknowledges that a breach by the other PARTY of this JDA may cause the non-breaching PARTY irreparable harm, for which an award of damages would not be adequate compensation and, in the event of such a breach or threatened breach, the non-breaching PARTY shall be entitled to seek equitable relief, including in the form of a restraining order, orders for preliminary or permanent injunction, specific performance and any other relief that may be available from any court, and the PARTIES hereby waive any requirement for the securing or posting of any bond or the showing of actual monetary damages in connection with such relief. These remedies shall not be deemed to be exclusive but shall be in addition to all other remedies available under this JDA at law or in equity, subject to any express exclusions or limitations in this JDA to the contrary.

Redactions with respect to certain portions hereof denoted with “***”

10. Representations, Warranties, Indemnity, Insurance & Compliance

- 10.1. Authority.** Each of the PARTIES represents as of the EFFECTIVE DATE and warrants for the TERM that it has authority to enter into this JDA and to perform its obligations under this JDA and that it has been duly authorized to sign and to deliver this JDA.

- 10.2. Compliance with LAWS.** The PARTIES will comply with all applicable laws, rules and regulations, including, but not limited to: (i) the federal anti-kickback statute (42 U.S.C. §1320a-7b) and the related safe harbor regulations and (ii) the Limitation on Certain Physician Referrals, also referred to as the “Stark Law” (42 U.S.C. §1395nn); (iii) The Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.); (iv) the Public Health Service Act (42 U.S.C. § 201 et seq.); (v) the Health Insurance Portability and Accountability Act of 1996 and the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”); (vi) any and all applicable U.S. export control laws and regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department’s Office of Foreign Asset Controls; and (vii) all comparable state and local laws and regulations relating to the conduct of the PROJECT. No part of any consideration paid hereunder is a prohibited payment for the recommending or arranging for the referral of business or the ordering of items or services, nor are the payments intended to induce illegal referrals of business. In the event that any part of this JDA is determined to violate federal, state, or local laws, rules, or regulations, the PARTIES agree to negotiate in good faith revisions to the provision or provisions that are in violation. In the event the PARTIES are unable to agree to new or modified terms as required to bring the entire JDA into compliance, either PARTY may terminate this JDA on *** written notice to the other PARTY.

- 10.3. Conflict of Interest.** COMPANY acknowledges that CCF maintains and adheres to a Conflict of Interest Policy. In that connection, COMPANY represents that, to COMPANY’s knowledge, no CCF employees, officers, or directors are owners, consultants, employees, officers or directors of COMPANY or any of its AFFILIATES or serve on any boards or committees of or in any advisory capacity with COMPANY or any of its AFFILIATES.

- 10.4. Insurance.** COMPANY represents and warrants that it has and shall maintain comprehensive general liability insurance coverage on either a self-insured or indemnity basis to protect against liability under this provision in amounts equal to *** and, upon request, COMPANY agrees to furnish to CCF evidence of insurance acceptable to CCF indicating the required coverage. COMPANY agrees to give CCF at least *** prior written notice in the event of any material, adverse change in such insurance.

- 10.5. Liability.** Except for damages arising from a breach of Article 4, fraud, willful misconduct or gross negligence, or as may be payable pursuant to a PARTY’s indemnification obligations under Paragraph 10.6, neither PARTY shall be liable to the other PARTY for any special, indirect, consequential or punitive damages of any kind, including, but not limited to, loss of profits, arising in any manner from this JDA regardless of the foreseeability thereof.

10.6. Indemnity.

- 10.6.1. COMPANY Indemnification.** Subject to Paragraph 10.6.3, COMPANY will indemnify, defend and hold harmless CCF and its respective trustees, directors, officers, medical and professional staff, employees, students, and agents and their respective successors, heirs, and assigns (each a “CCF Indemnitee”), against all LOSSES arising from any THIRD PARTY claim, suit, action or other proceeding (each, an “COVERED CLAIM”) which may be made

or instituted against any CCF Indemnitee related to, arising out of or resulting from (a) COMPANY's material breach of any representation, warranty, covenant or obligation under this JDA, (b) use by COMPANY or any of its transferees of any CCF INVENTION or JOINT INVENTION, (c) any use, sale, transfer or other disposition by COMPANY or its transferees of a PRODUCT or any other products made by use of CCF INVENTION or JOINT INVENTION, except to the extent any such COVERED CLAIM arises from any matter for which CCF is obligated to provide indemnification pursuant to Paragraph 10.6.2.

- 10.6.2. CCF Indemnification.** Subject to Paragraph 10.6.3, to the extent allowed under applicable laws, CCF will indemnify, defend and hold harmless COMPANY and its respective directors, officers, employees, consultants, and agents and their respective successors, heirs, and assigns (each a "**COMPANY Indemnitee**"), against all LOSSES arising from any COVERED CLAIM which may be made or instituted against any COMPANY Indemnitee related to, arising out of or resulting from (a) CCF's material breach of any representation, warranty, covenant or obligation under this JDA, or (b) a CCF Indemnitee's negligence, willful misconduct, or breach of any applicable law, except to the extent any such COVERED CLAIM arises from any matter for which COMPANY is obligated to provide indemnification pursuant to Paragraph 10.6.1.

Redactions with respect to certain portions hereof denoted with "****"

- 10.6.3. Indemnification Procedure.** An Indemnitee (whether a CCF Indemnitee or a COMPANY Indemnitee) that intends to claim indemnification under this Paragraph 10.6 will give notice to the indemnifying PARTY of any COVERED CLAIM which might be covered by this Paragraph 10.6. The indemnifying PARTY shall immediately take control of the defense and investigation of the COVERED CLAIM, including selection of counsel reasonably acceptable to the Indemnitee, at the indemnifying PARTY's sole cost and expense; provided, however, that the indemnifying PARTY will not, without the prior written consent of the Indemnitee, settle or consent to the entry of any judgment with respect to such COVERED CLAIM (a) that does not release the Indemnitee from all liability with respect to such COVERED CLAIM, or (b) that may adversely affect the Indemnitee or under which the Indemnitee would incur any obligation or liability, other than one as to which the indemnifying PARTY has an indemnity obligation hereunder. The Indemnitee agrees to cooperate and provide reasonable assistance to such defense at the indemnifying PARTY's expense. The Indemnitee at all times reserves the right to select and retain counsel of its own at its own expense to defend its interests, provided that the indemnifying PARTY will remain in control of the defense. The Indemnitee's failure to perform any obligations under this Paragraph 10.6.3 shall not relieve the indemnifying PARTY of its obligation under Paragraph 10.6 except to the extent that the indemnifying PARTY can demonstrate that it has been materially prejudiced as a result of the failure.

- 10.7. DISCLAIMER OF WARRANTIES BY CCF.** EXCEPT AS PROVIDED HEREIN AND TO THE EXTENT PERMITTED BY APPLICABLE LAW, CCF MAKES NO WARRANTIES, EXPRESSED OR IMPLIED, AS TO ANY MATTER WHATSOEVER, INCLUDING, WITHOUT LIMITATION, THE CONDITION OF THE PROJECT (INCLUDING ANY RESULTS THEREFROM) OR ANY IP (INCLUDING, BUT NOT LIMITED TO, CCF INVENTIONS, JOINT INVENTIONS OR BACKGROUND IP) OR ANY PRODUCT(S), WHETHER TANGIBLE OR INTANGIBLE, CONCEIVED, DISCOVERED, OR DEVELOPED UNDER THIS JDA; OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE PROJECT OR ANY IP OR PRODUCT; OR FREEDOM FROM PATENT, TRADEMARK, OR COPYRIGHT INFRINGEMENT, INFORMATIONAL CONTENT, INTEGRATION, OR THEFT OF TRADE SECRETS AND DOES NOT ASSUME ANY LIABILITY HEREUNDER FOR ANY INFRINGEMENT OF ANY PATENT, TRADEMARK, OR COPYRIGHT ARISING FROM THE USE OF INFORMATION, RESULTS OR DELIVERABLES OR RIGHTS GRANTED OR PROVIDED BY IT HEREUNDER. IN ADDITION, NOTHING IN THIS JDA MAY BE DEEMED A REPRESENTATION OR WARRANTY BY CCF AS TO THE VALIDITY OF ANY OF CCF'S PATENT RIGHTS OR THEIR REGISTRABILITY OR OF THE ACCURACY, SAFETY, EFFICACY, OR USEFULNESS, FOR ANY PURPOSE, OF ANY IP.

- 10.8. DISCLAIMER OF WARRANTIES BY COMPANY.** EXCEPT AS PROVIDED HEREIN AND TO THE EXTENT PERMITTED BY THE APPLICABLE LAW, COMPANY MAKES NO WARRANTIES OF ANY KIND, EXPRESSED OR IMPLIED, AS TO ANY MATTER WHATSOEVER, INCLUDING WITH RESPECT TO ANY OF COMPANY'S TECHNOLOGIES THAT WILL BE SUBJECT TO THIS JDA. IN PARTICULAR, COMPANY MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE TECHNOLOGIES WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR

OTHER RIGHTS OF ANY THIRD PARTY. IN ADDITION, NOTHING IN THIS JDA MAY BE DEEMED A REPRESENTATION OR WARRANTY BY COMPANY AS TO THE VALIDITY OF ANY OF COMPANY'S PATENTS OR THEIR REGISTRABILITY OR OF THE ACCURACY, SAFETY, EFFICACY, OR USEFULNESS, FOR ANY PURPOSE, OF THE TECHNOLOGIES.

Redactions with respect to certain portions hereof denoted with "****"

11. Miscellaneous

- 11.1. Agreement Negotiated.** The form of this JDA has been negotiated by or on behalf of the respective PARTIES, each of which was represented by attorneys who have carefully negotiated the provisions hereof. Each PARTY acknowledges that it has been advised to, and has had the opportunity to consult with its attorney(s) prior to entering into this JDA. No law or rule relating to the construction or interpretation of contracts against the drafter of any particular clause should be applied with respect to this JDA.
- 11.2. Applicable Law.** All matters arising under or relating to this JDA are governed by the laws of the State of Ohio, without regard to any principle of conflict or choice of laws that would cause the application of the laws of any other jurisdiction. Despite the above, the substantive law of the country of any PATENT RIGHTS governs the validity and enforceability of the subject PATENT RIGHTS.
- 11.3. Counterparts.** This JDA may be executed in one or more counterparts, each of which will be deemed to be an original, but all of which will constitute one and the same instrument. A facsimile or .PDF copy of a signature of a PARTY will have the same effect and validity as an original signature.
- 11.4. Entire Agreement / Amendments.** This JDA, including any attached Schedules, and the License Agreement, including any attached appendices or exhibits, constitute the entire understanding between the PARTIES with respect to the subject matter contained herein and supersedes all prior agreements, understandings and arrangements whether oral or written between the PARTIES relating to the subject matter hereof, except as expressly set forth herein. Nothing in this JDA may be changed or modified, nor may anything be added to this JDA, except as may be specifically agreed to in a subsequent writing executed with the same formalities as this JDA.
- 11.5. Force Majeure.** No PARTY will be responsible for delays or failures to perform resulting from events beyond its control but will have a responsibility to mitigate any damage which might arise as a result of any such event. Such events will include, but not be limited to: acts of nature, epidemics; fire; government restrictions or other government acts; insurrection; power failures; strike, union disturbance, or other labor problems; riots; terrorism or threats of terrorism; or war (whether or not declared); earthquakes, floods, or other disasters. Upon the occurrence of any event of the type referred to in this Paragraph 11.5, the affected PARTY will give prompt written notice to the other PARTY, together with a description of the event and the duration for which the affected PARTY expects its ability to comply with the provisions of this JDA to be affected. The affected PARTY will devote its commercially reasonable efforts to remedy to the extent possible the condition giving rise to the failure event and to resume performance of its obligations under this JDA as promptly as possible.
- 11.6. Headings.** The headings or titles of Articles, Sections, Paragraphs, or Schedules appearing in this JDA are provided for convenience and are not to be used in construing this JDA. All references to Articles, Paragraphs, Sections and/or Schedules will be to Articles, Paragraphs, Sections, and/or Schedules of this JDA, unless specifically noted otherwise. Reference to an "Article," "Section," or "Paragraph" includes the referenced Article, Section or Paragraph, and all sub-sections and sub-paragraphs included within the referenced Article, Section or Paragraph.

Redactions with respect to certain portions hereof denoted with "****"

- 11.7. Joint Research Agreement Statement for US Patent Prosecution.** A PARTY desiring to invoke 35 USC §103(c)(2) and post American Invents Act 35 USC §102(c) during the PROSECUTION of PATENT RIGHTS, will be permitted to

disclose the existence of this JDA and the names of the PARTIES thereto, and to make the statement required by 37 CFR §1.104(c)(4)(iii) on the record during PROSECUTION. Despite the foregoing, neither PARTY will be obligated to execute documents necessary for invoking 35 USC §103(c)(2) and post American Invents Act 35 USC §102(c).

11.8. No Other Rights Granted. Except as may be expressly set forth in this JDA, no PARTY grants, by implication, estoppel, or otherwise, any assignment, license or other rights in any of its or its AFFILIATES' IP or CONFIDENTIAL INFORMATION to the other PARTY or its AFFILIATES.

11.9. No Third Party Beneficiaries. Despite anything in this JDA to the contrary, nothing in this JDA, expressed or implied, is intended to confer on any person or entity other than the PARTIES or their respective permitted successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this JDA.

11.10. No Waiver. No omission or delay by either PARTY at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants, or provisions of this JDA by another PARTY at any time designated, will be a waiver of any such right or remedy to which such PARTY is entitled, nor will it in any way affect the right of such PARTY to enforce such provisions thereafter.

11.11. Non-assignability. This JDA will be binding upon and inure to the benefit of the respective PARTIES and successors or assigns of all or substantially all of the relevant business or assets of either PARTY to which this JDA relates (whether by merger, consolidation, stock purchase, asset purchase or otherwise), and will otherwise be nontransferable and non-assignable to THIRD PARTIES without the prior express written consent of the other PARTY; provided, however, CCF may assign its reserved rights under Paragraph 6.4 to any academic, government, or not-for-profit institution without COMPANY's consent.

11.12. Notices. All notices under this JDA will be sent to the respective PARTIES at the following addresses (or such other addresses as a PARTY designates to the other PARTY by written notice) by certified or registered mail, or sent by a nationally recognized overnight courier service; and will be deemed to have been given one day after being sent:

If to CCF: The Cleveland Clinic Foundation
9500 Euclid Avenue
Cleveland, OH 44195
Attn: CCF Innovations (Mail code: GCIC10)
email: giordat@ccf.org
With copy to: ccilicense@ccf.org

with a copy to: Law Department - (Mail Code: AC321)
Attn: Research Contracts (Innovations)
The Cleveland Clinic Foundation
3050 Science Park Drive
Beachwood, OH 44122
Attn: Chief Legal Counsel, CC Innovations
Email: legalcontracts@ccf.org
With copy to: cicarej@ccf.org

Payments to: ***

Redactions with respect to certain portions hereof denoted with “***”

If to COMPANY: Anixa Biosciences, Inc.
3150 Almaden Expressway, Suite 250
San Jose, CA 95118
Attention: Amit Kumar, CEO
Email: ak@anixa.com

11.13. Partial Invalidity. If any covenant, condition or other provision of this JDA is held invalid, void or illegal by any court of competent jurisdiction, then the same will be deemed severable from the remainder of the subject agreement and will in no way affect, impair or invalidate any other covenant, condition or provision, and will be deemed replaced by a provision which comes closest to such unenforceable provision in language and intent, without being invalid, void or illegal.

11.14. Use of Name and Press Releases. Neither PARTY shall use the name, logo, likeness, trademarks, or image of the other PARTY for advertising, marketing, endorsement or any other purposes without the specific prior written consent of an authorized representative of the other PARTY as to each such use. Neither PARTY shall make any public announcements, make any public statements, issue any press releases or otherwise communicate with any news media in respect of this JDA or the transactions contemplated hereby without the specific prior written consent of an authorized representative of the other PARTY. COMPANY shall not be required to attain consent under this Paragraph 11.14 for use that, based on the written legal opinion of COMPANY's legal counsel, is required pursuant to applicable law or regulation, including COMPANY's obligations under disclosure rules of the Securities and Exchange Commission (SEC). CCF's specific prior written consent to one use shall apply only to other uses of substantially similar form and content (e.g. various iterations of investor presentations) but not to any other uses. Notwithstanding anything to the contrary contained herein, CCF shall have the right to withdraw any consent previously provided (e.g., if CCF has previously consented to COMPANY's use of CCF's name and logo on COMPANY's website or in investor presentations). For clarity, this Paragraph 11.14 shall not restrict COMPANY (or its AFFILIATES or sublicensees) from publicly disclosing information regarding the status of the development, or manufacture or commercialization of any PRODUCT, provided that any such disclosure does not use the name, logo, likeness, trademark or image of CCF.

11.15. Export Control. It is understood that CCF is subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes, and other commodities and that its obligations hereunder are contingent on compliance with applicable United States export laws and regulations. It is the expectation of CCF that the work done pursuant to this JDA will constitute fundamental research under the applicable export control laws and regulations. CCF does not wish to take receipt of export-controlled information except as may be knowingly and expressly agreed to in writing signed by an authorized representative of CCF and for which CCF has made specific arrangements. COMPANY acknowledges that CCF has foreign nationals on CCF's campus who may have access to technical data, computer software, laboratory prototypes, and other commodities associated with this JDA. COMPANY agrees that it will not provide or make accessible to CCF any non-EAR 99 materials (including, without limitation, equipment, information and/or data) without first informing CCF of the export-controlled nature of the materials and obtaining from CCF's RESEARCH OFFICE its prior written consent to accept such materials as well as any specific instructions regarding the mechanism pursuant to which such materials should be passed to CCF. COMPANY agrees to comply with any and all applicable U.S. export control laws and regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department's Office of Foreign Asset Controls.

11.16. Relationship Between the PARTIES. Both PARTIES are independent contractors under this JDA. This JDA does not constitute making either PARTY the agent or legal representative of the other PARTY, for any purpose whatsoever. Neither PARTY is granted any right or authority to assume or to create any obligation or responsibility, expressed or implied, on behalf of or in the name of the other PARTY or to bind the other PARTY in any manner or thing whatsoever. No employment relationship, agency, joint venture or partnership between the PARTIES is intended nor will be inferred. Neither PARTY's employees will represent themselves as being representatives of or otherwise employed by the other PARTY.

11.17. Mutual Drafting. Each PARTY hereby represents that it has been, or has had the opportunity to be, represented by legal counsel of its choice in connection with the negotiation and execution of this JDA. This JDA shall be construed as if drafted jointly by the PARTIES hereto and no presumption or burden of proof shall arise favoring or disfavoring any PARTY by virtue of the authorship of any provision of this JDA.

Signature page follows

Redactions with respect to certain portions hereof denoted with “****”

IN WITNESS WHEREOF, the PARTIES, by their authorized representatives, have evidenced their consent to the terms provided herein by signing below.

/s/ Steven C. Glass

Signature

Steven C. Glass

Printed Name

Chief Financial Officer

Title

1/26/2021

Date

/s/ Amit Kumar

Signature

Amit Kumar

Printed Name: Amit Kumar

CEO

Title: CEO

1/21/21

Date

Schedule A – WORK PLAN

[see attached]

Statement of Work for Licensing Agreement with Anixa**1. Apply to NCI for Performing the Ovarian Cancer Vaccine Preclinical Development**

The National Cancer Institute Division of Cancer Prevention has established a Cancer Preclinical Drug Development Program called **PREVENT**. The **PREVENT** program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. All interested researchers with novel concepts are eligible to apply. **PREVENT** is not a grant program, but allocates NCI contract resources and expertise to generate data and materials, which are used by the applicants for further development. **PREVENT**'s current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.

<https://prevention.cancer.gov/major-programs/prevent-cancer-preclinical-drug-development-program>

Submission deadlines to **PREVENT** occur twice per year on the second Monday in January and July. The next deadlines are January 11, 2021 or July 12, 2021. Here are the [Instructions for Applying](#). Here is the latest [application template](#).

Available Resources Provided by PREVENT

- *In vitro* and *in vivo* efficacy studies and preclinical pharmacology
- Various carcinogen-induced and genetically engineered animal models of cancer
- Identification and evaluation of intermediate biomarkers
- PK and PK/PD modeling to evaluate efficacy and optimize dosing regimen
- Characterization of immune responses to vaccines and immunomodulatory agents
- Formulation optimization for enhanced bioavailability and clinical usefulness
- Analytical method development for investigational agents in bulk form and in biological fluids and tissues
- Scale-up cGMP and non-cGMP production of an investigational agent
- Stability testing for bulk and formulated material
- Preclinical investigational new drug (IND)-directed GLP toxicology studies
- Regulatory support
- Other resources to support drug development

2. Data Needed for PREVENT Application

The ID8 ovarian cancer mouse model is the preferred model at NCI for determining ovarian cancer prevention. We know that AMHR2-ED is expressed in ID8 tumors, but we need to generate the following data for our application:

- a. Generate Publishable Quality Data Showing Expression of AMHR2-ED in ID8 Tumors
- b. Determine Efficacy of Prophylactic AMHR2-ED Vaccination Using *s.c.* Inoculation of ID8
- c. Determine Efficacy of Therapeutic AMHR2-ED Vaccination Using *s.c.* Inoculation of ID8
- d. Determine Efficacy of Prophylactic AMHR2-ED Vaccination Using *i.p.* Inoculation of ID8
- e. Determine Efficacy of Therapeutic AMHR2-ED Vaccination Using *i.p.* Inoculation of ID8
- f. Determine Long-Term Expression of Serum Antibody Titers to AMHR2-ED

3. AMHR2-ED Vaccination Data to Be Generated Over the Next Two Years

- a. Determine Compatibility of AMHR2-ED Vaccination and Anti PD-1/Anti-PD-L1 Treatment
 - b. Determine Compatibility of AMHR2-ED Vaccination and Lucitinab Treatment
 - c. Determine Compatibility of AMHR2-ED Vaccination and Anti-TIGIT Treatment
 - d. Determine Compatibility of AMHR2-ED Vaccination and Treatment with PARP Inhibitors
 - e. Determine Compatibility of AMHR2-ED Vaccination and Treatment with Cisplatin
 - f. Determine Expression of AMHR2-ED in Endometrial Cancer
-

CERTIFICATION

I, Dr. Amit Kumar, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Anixa Biosciences, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Dr. Amit Kumar

Dr. Amit Kumar
Chairman, President and
Chief Executive Officer
(Principal Executive Officer)

March 11, 2021

CERTIFICATION

I, Michael J. Catelani, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Anixa Biosciences, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Michael J. Catelani

Michael J. Catelani
Chief Operating Officer and
Chief Financial Officer
(Principal Financial and Accounting Officer)

March 11, 2021

Statement of Chief Executive Officer
Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Dr. Amit Kumar, the Chairman, President and Chief Executive Officer of Anixa Biosciences, Inc., hereby certifies that:

1. The Company's Form 10-Q Quarterly Report for the period ended January 31, 2021 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Dr. Amit Kumar

Dr. Amit Kumar
Chairman, President and
Chief Executive Officer
(Principal Executive Officer)

March 11, 2021

Statement of Chief Financial Officer
Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Michael J. Catelani, the Chief Operating Officer and Chief Financial Officer of Anixa Biosciences, Inc., hereby certifies that:

1. The Company's Form 10-Q Quarterly Report for the period ended January 31, 2021 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Michael J. Catelani

Michael J. Catelani
Chief Operating Officer and
Chief Financial Officer
(Principal Financial and Accounting Officer)

March 11, 2021

**Document and Entity
Information - shares**

3 Months Ended
Jan. 31, 2021 Mar. 11, 2021

[Cover \[Abstract\]](#)

Entity Registrant Name	Anixa Biosciences Inc	
Entity Central Index Key	0000715446	
Document Type	10-Q	
Document Period End Date	Jan. 31, 2021	
Amendment Flag	false	
Current Fiscal Year End Date	--10-31	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Entity Filer Category	Non-accelerated Filer	
Entity Small Business Flag	true	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Entity Common Stock, Shares Outstanding		26,705,514
Document Fiscal Period Focus	Q1	
Document Fiscal Year Focus	2021	

**Condensed Consolidated
Balance Sheets - USD (\$)**

Jan. 31, 2021 Oct. 31, 2020

Current assets:

<u>Cash and cash equivalents</u>	\$ 11,982,870	\$ 6,417,061
<u>Short-term investments in certificates of deposit</u>	2,000,000	2,640,000
<u>Prepaid expenses and other current assets</u>	581,320	311,563
<u>Total current assets</u>	14,564,190	9,368,624
<u>Operating lease right-of-use asset</u>	40,212	54,340
<u>Other assets</u>		30,000
<u>Total assets</u>	14,604,402	9,452,964

Current liabilities:

<u>Accounts payable</u>	511,816	232,368
<u>Accrued expenses</u>	972,835	901,025
<u>Operating lease liability</u>	40,836	55,198
<u>Total current liabilities</u>	1,525,487	1,188,591

Commitments and contingencies (Note 9)

Shareholders' equity:

<u>Preferred stock, value</u>		
<u>Common stock, par value \$.01 per share; 100,000,000 shares authorized; 26,179,122 and 24,248,695 shares issued and outstanding, respectively</u>	261,791	242,486
<u>Additional paid-in capital</u>	207,382,102	200,354,488
<u>Accumulated deficit</u>	(194,043,909)	(191,835,618)
<u>Total shareholders' equity</u>	13,599,984	8,761,356
<u>Noncontrolling interest (Note 1)</u>	(521,069)	(496,983)
<u>Total equity</u>	13,078,915	8,264,373
<u>Total liabilities and equity</u>	14,604,402	9,452,964

Series A Convertible Preferred Stock [Member]

Shareholders' equity:

Preferred stock, value

**Condensed Consolidated
Balance Sheets
(Parenthetical) - \$ / shares**

Jan. 31, 2021 Oct. 31, 2020

Preferred stock, par value	\$ 100	\$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued		
Preferred stock, shares outstanding		
Common stock, par value	\$ 0.01	\$.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	26,179,122	24,248,695
Common stock, shares outstanding	26,179,122	24,248,695
Series A Convertible Preferred Stock [Member]		
Preferred stock, par value	\$ 100	\$ 100
Preferred stock, shares authorized	140	140
Preferred stock, shares issued		
Preferred stock, shares outstanding		

**Condensed Consolidated
Statements of Operations
(Unaudited) - USD (\$)**

**3 Months Ended
Jan. 31, Jan. 31,
2021 2020**

Income Statement [Abstract]

<u>Revenue</u>	\$ 512,500	
<u>Operating costs and expenses:</u>		
<u>Inventor royalties, contingent legal fees, litigation and licensing expenses</u>	385,002	
<u>Research and development expenses (including non-cash share-based compensation expenses of \$290,207 and \$397,523, respectively)</u>	827,651	1,490,588
<u>General and administrative expenses (including non-cash share-based compensation expenses of \$695,892 and \$623,811, respectively)</u>	1,532,978	1,139,281
<u>Total operating costs and expenses</u>	2,745,631	2,629,869
<u>Loss from operations</u>	(2,233,131)	(2,629,869)
<u>Interest income</u>	754	13,294
<u>Net loss</u>	(2,232,377)	(2,616,575)
<u>Less: Net loss attributable to noncontrolling interest</u>	(24,086)	(24,032)
<u>Net loss attributable to common shareholders</u>	\$ (2,208,291)	\$ (2,592,543)
 <u>Net loss per common share attributable to common shareholders: Basic and diluted</u>	 \$ (0.09)	 \$ (0.13)
<u>Weighted average common shares outstanding: Basic and diluted</u>	25,164,565	20,703,882

**Condensed Consolidated
Statements of Operations
(Unaudited) (Parenthetical) -
USD (\$)**

3 Months Ended

Jan. 31, 2021 Jan. 31, 2020

Research and Development Expense [Member]

Non-cash share based compensation expenses \$ 290,207 \$ 397,523

General and Administrative Expense [Member]

Non-cash share based compensation expenses \$ 695,892 \$ 623,811

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD (\$)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total Shareholders' Equity [Member]	Non- controlling Interest [Member]	Total
Beginning balance at Oct. 31, 2019	\$ 203,317	\$ 186,849,299	\$ (181,817,263)	\$ 5,235,353	\$ (422,975)	\$ 4,812,378
Beginning balance, shares at Oct. 31, 2019	20,331,754					
Stock option compensation to employees and directors		963,880		963,880		963,880
Stock options and warrants issued to consultants		57,454		57,454		57,454
Common stock issued upon exercise of stock options	\$ 189	28,291		28,480		28,480
Common stock issued upon exercise of stock options, shares	18,900					
Common stock issued in at-the-market offering	\$ 4,907	1,747,076		1,751,983		1,751,983
Common stock issued in at-the-market offering, shares	490,655					
Net loss			(2,592,543)	(2,592,543)	(24,032)	(2,616,575)
Ending balance at Jan. 31, 2020	\$ 208,413	189,646,000	(184,409,806)	5,444,607	(447,007)	4,997,600
Ending balance, shares at Jan. 31, 2020	20,841,309					
Beginning balance at Oct. 31, 2020	\$ 242,486	200,354,488	(191,835,618)	8,761,356	(496,983)	8,264,373
Beginning balance, shares at Oct. 31, 2020	24,248,695					
Stock option compensation to employees and directors		874,862		874,862		874,862
Stock options and warrants issued to consultants		111,237		111,237		111,237
Common stock issued upon exercise of stock options	\$ 299	103,925		104,224		104,224
Common stock issued upon exercise of stock options, shares	29,880					
Common stock issued in at-the-market offering	\$ 19,006	5,937,590		5,956,596		5,956,596
Common stock issued in at-the-market offering, shares	1,900,547					
Net loss			(2,208,291)	(2,208,291)	(24,086)	(2,232,377)
Ending balance at Jan. 31, 2021	\$ 261,791	\$ 207,382,102	\$ (194,043,909)	\$ 13,599,984	\$ (521,069)	\$ 13,078,915

Ending balance, shares at Jan. 26,179,122
31, 2021

**Condensed Consolidated
Statements of Shareholders'
Equity (Parenthetical) - USD
(\$)**

3 Months Ended

Jan. 31, 2021 Jan. 31, 2020

[Statement of Stockholders' Equity \[Abstract\]](#)

[Stock issued, offering expenses](#)

\$ 184,510 \$ 100,972

**Condensed Consolidated
Statements of Cash Flows
(Unaudited) - USD (\$)**

**3 Months Ended
Jan. 31, 2021 Jan. 31, 2020**

Reconciliation of net loss to net cash used in operating activities:

<u>Net loss</u>	\$ (2,232,377)	\$ (2,616,575)
<u>Stock option compensation to employees and directors</u>	874,862	963,880
<u>Stock options and warrants issued to consultants</u>	111,237	57,454
<u>Depreciation of property and equipment</u>		14,998
<u>Gain on sale of equipment</u>	(5,447)	
<u>Amortization of operating lease right-to-use asset</u>	14,128	12,314

Change in operating assets and liabilities:

<u>Prepaid expenses and other current assets</u>	(269,757)	74,698
<u>Accounts payable</u>	279,448	(218,719)
<u>Accrued expenses</u>	71,810	(190,464)
<u>Operating lease liability</u>	(14,362)	(12,002)
<u>Net cash used in operating activities</u>	(1,170,458)	(1,914,416)

Cash flows from investing activities:

<u>Disbursements to acquire short-term investments in certificates of deposit</u>	(1,000,000)	(1,870,000)
<u>Proceeds from maturities of short-term investments in certificates of deposit</u>	1,640,000	1,350,000
<u>Purchase of property and equipment</u>		(15,790)
<u>Proceeds from sale of equipment</u>	35,447	
<u>Net cash provided by (used in) investing activities</u>	675,447	(535,790)

Cash flows from financing activities:

<u>Net proceeds from sale of common stock in at-the-market offering</u>	5,956,596	1,751,983
<u>Proceeds from exercise of stock options</u>	104,224	28,480
<u>Net cash provided by financing activities</u>	6,060,820	1,780,463
<u>Net increase (decrease) in cash and cash equivalents</u>	5,565,809	(669,743)
<u>Cash and cash equivalents at beginning of period</u>	6,417,061	3,491,625
<u>Cash and cash equivalents at end of period</u>	11,982,870	2,821,882

Supplemental cash flow information:

<u>Cash proceeds from interest income</u>	\$ 1,134	\$ 14,468
---	----------	-----------

[Accounting Policies](#)

[\[Abstract\]](#)

[Business and Funding](#)

1. BUSINESS AND FUNDING

Description of Business

As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Our primary operations involve developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. Our therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (“CAR-T”) technology, initially focused on treating ovarian cancer, and discovery and ultimately development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Our vaccine programs include the development of a vaccine against breast cancer, specifically triple negative breast cancer (“TNBC”), the most lethal form of the disease, and a vaccine against ovarian cancer.

Our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), is developing immunotherapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”) relating to Wistar’s CAR-T technology. We have initially focused on the development of a treatment for ovarian cancer, but we may also pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent (5%) of the common stock of Certainty.

Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), is advancing toward human clinical testing its CAR-T technology for treating ovarian cancer. We are currently testing the clinical grade vector and preparing an Investigational New Drug (“IND”) application for submission to the U.S. Food and Drug Administration (“FDA”). We anticipate filing the IND in the first calendar quarter of 2021. Assuming the FDA approves our IND application, we anticipate beginning the human clinical trials during the second half of 2021.

In April 2020, we entered into a collaboration with OntoChem GmbH (“OntoChem”), to discover and ultimately develop anti-viral drug candidates against COVID-19. Through this collaboration, we utilized advanced computational methods, machine learning, and molecular modeling techniques to perform *in silico* screening of over 1.2 billion compounds in chemical libraries (including publicly available compounds and OntoChem’s proprietary libraries) to evaluate if any of these compounds could disrupt one of two key enzymes of SARS-CoV-2, the virus that causes the disease COVID-19.

The screening process resulted in the identification of multiple compounds that could potentially disrupt critical enzymes of the virus. Several of these compounds were synthesized and tested in *in vitro* biological assays. Upon completion of these biological assays, we identified two of the most promising compounds and have begun testing them in animal models. In these animal studies, the two compounds are being compared to Remdesivir, which is the only anti-viral drug authorized by the FDA for COVID-19. We anticipate this proof-of-concept animal study to be completed by the end of the first calendar quarter of 2021.

We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. We are working in

collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused specifically on TNBC. A specific protein, alpha-lactalbumin, has been identified that is only present during lactation in healthy women, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. In December 2020, we received authorization from the FDA to commence enrollment and treatment of patients in a Phase 1a clinical trial. We are performing the activities necessary to prepare for treatment of patients in the Phase 1a clinical trial, and we anticipate being prepared to treat the first enrolled patient by mid-year 2021.

In November 2020, we executed a license agreement with Cleveland Clinic pursuant to which the Company was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. This technology pertains to the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor II protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines after menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. We entered into a joint development agreement with Cleveland Clinic, to advance this vaccine technology toward human clinical testing.

Over the next several quarters, we expect the development of our breast and ovarian cancer vaccines, our COVID-19 therapeutic program and Certainty’s CAR-T technology to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities regarding the Cchek™ liquid biopsy platform (operations for which were suspended in July 2020), as well as in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management.

Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and vaccine programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin generating revenue with respect to any of our current therapy or vaccine programs in the near term. We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as therapeutics or vaccines. The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials.

Funding and Management’s Plans

Based on currently available information as of March 11, 2021, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. During the three months ended January 31, 2021, we raised approximately \$5,957,000, net of expenses, through an at-the-market equity offering of 1,900,547 shares of common stock, under which offering we may issue up to \$50 million of common stock. Under our at-the-market equity program which is currently effective and may remain available for us to use in the future, as of January 31, 2021, we may sell an additional approximately \$34,670,000 of common stock. We

may seek to obtain working capital during our fiscal year 2021 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt could result in dilution to our stockholders. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2020. The accompanying October 31, 2020 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of January 31, 2021, and results of operations and cash flows for the interim periods represented. The results of operations for the three months ended January 31, 2021 are not necessarily indicative of the results to be expected for the entire year.

Noncontrolling Interest

Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2021:

Balance, October 31, 2020	\$ (496,983)
Net loss attributable to noncontrolling interest	(24,086)
Balance, January 31, 2021	<u>\$ (521,069)</u>

Revenue Recognition

Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive.

We follow the accounting guidance of Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. In accordance with ASC 606 we are required to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time.

Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.

Cost of Revenues

Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations.

Research and Development Expenses

Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, preventative cancer vaccines and antiviral drug candidates for COVID-19, are expensed in the accompanying condensed consolidated financial statements in the period incurred.

Stock Based Compensation

3 Months Ended

Jan. 31, 2021

[Share-based Payment
Arrangement \[Abstract\]
Stock Based Compensation](#)

2. STOCK BASED COMPENSATION

The Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants.

Stock Option Compensation Expense

The compensation cost for service-based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to four years. We recorded stock-based compensation expense related to service-based stock options granted to employees and directors of approximately \$875,000 and \$964,000 during the three months ended January 31, 2021 and 2020.

For stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company's common stock exceeding certain price targets, we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). On May 8, 2018, we issued market condition options to purchase 1,500,000 shares of common stock, to our Chairman, President and Chief Executive Officer, vesting at target trading prices of \$5.00 to \$8.00 per share before May 31, 2021, with implied service periods of three to seven months. In October 2018, the first tranche of 500,000 shares of market condition options became exercisable upon achieving an average closing price above \$5.00 per share for twenty consecutive trading days. We did not record any market condition stock-based compensation expense during the three months ended January 31, 2021 and 2020.

The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately \$54,000 and \$57,000 during the three months ended January 31, 2021 and 2020, respectively.

Stock Option Plans

During the three months ended January 31, 2021, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the "2010 Share Plan") and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the "2018 Share Plan"), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018.

During the three months ended January 31, 2020, the remaining outstanding options under the Anixa Biosciences, Inc. 2003 Share Incentive Plan (the "2003 Plan") expired.

Stock Option Activity

During the three months ended January 31, 2021 and 2020, we granted options to purchase 1,130,000 shares and 800,000 shares of common stock, respectively, to employees and consultants, with exercise prices ranging from \$2.83 to \$4.04 per share, pursuant to the 2018 Share Plan. During the three months ended January 31, 2021 and 2020, stock options to purchase

29,880 and 18,900 shares of common stock, respectively, were exercised with aggregate proceeds of approximately \$104,000 and \$28,000, respectively.

2003 Plan

The 2003 Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2003 Plan, the plan terminated with respect to the ability to grant future awards on April 21, 2013. Information regarding the 2003 Plan for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2019	400	\$ 17.00	
Forfeited/Expired	(400)	\$ 17.00	
Options outstanding and exercisable at January 31, 2020	-	\$ -0-	\$ -0-

2010 Plan

The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020. Information regarding the 2010 Share Plan for the three months ended January 31, 2021 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2020	1, 1,907,534	\$ 2.82	
Exercised	(6,000)	\$ 2.32	
Forfeited/Expired	(400)	\$ 5.75	
Options outstanding at January 31, 2021	1 1,901,134	\$ 2.82	\$ 1,906,253
Options exercisable at January 31, 2021	1, 1,823,634	\$ 2.83	\$ 1,822,053

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2021:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 0.67 - \$ 2.30	544,000	5.22	\$ 1.56	516,500	5.15	\$ 1.60

\$ 2.58 - \$ 3.13	833,000	3.11	\$ 2.79	833,000	3.54	\$ 2.79
\$ 3.46 - \$ 5.30	524,134	7.11	\$ 4.17	474,134	7.07	\$ 4.25

Information regarding the 2010 Share Plan for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options Outstanding at October 31, 2019	1,998,668	\$ 2.80	
Exercised	(18,900)	\$ 1.51	
Forfeited/Expired	(5,534)	\$ 2.58	
Options Outstanding at January 31, 2020	1,974,234	\$ 2.81	\$ 1,810,395
Options Exercisable at January 31, 2020	1,721,734	\$ 2.86	\$ 1,542,195

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2020:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 0.67 - \$2.30	561,500	6.28	\$ 1.56	464,000	6.03	\$ 1.69
\$ 2.58 - \$ 3.13	878,200	3.43	\$ 2.79	878,200	3.97	\$ 2.79
\$ 3.46 - \$ 5.75	534,534	7.94	\$ 4.16	379,534	7.76	\$ 4.45

2018 Plan

The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of January 31, 2021, the 2018 Share Plan had 2,000,000 shares available for future grants. Information regarding the 2018 Share Plan for the three months ended January 31, 2021 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2020	4,346,661	\$ 3.69	
Granted	1,130,000	\$ 2.83	
Exercised	(23,880)	\$ 3.78	
Forfeited/Expired	(392,781)	\$ 3.70	
Options outstanding at January 31, 2021	5,060,000	\$ 3.49	\$ 1,184,900
Options exercisable at January 31, 2021	2,312,640	\$ 3.69	\$ 147,579

The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2021:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 2.09 - \$3.70	3,975,000	8.12	\$ 3.38	1,664,862	7.47	\$ 3.61
\$ 3.84 - \$4.61	1,085,000	7.95	\$ 3.90	647,778	7.66	\$ 3.92

Information regarding the 2018 Share Plan for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options Outstanding at October 31, 2019	3,935,500	\$ 3.74	
Granted	800,000	\$ 3.85	
Options Outstanding at January 31, 2020	4,735,000	\$ 3.76	\$ -0-
Options Exercisable at January 31, 2020	1,798,616	\$ 3.74	\$ -0-

The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2020:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 3.70	3,100,000	8.27	\$ 3.70	1,433,334	8.27	\$ 3.70
\$ 3.84 - \$4.61	1,635,000	9.17	\$ 3.88	365,282	8.32	\$ 3.92

Outside of Share Plans

In addition to options granted under stock option plans, during the years ended October 31, 2012 and 2013, the Board of Directors approved the grant of stock options to certain employees and directors. Information regarding stock options that were granted outside of share plans for the three months ended January 31, 2021 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2020	1,698,000	\$ 2.58	

Options outstanding and exercisable at January 31, 2021	1,698,000	\$ 2.58	\$ 1,825,350
---	-----------	---------	--------------

The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2021:

Range of Exercise Prices	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 2.58	1,698,000	1.56	\$ 2.58

Information regarding stock options that were granted outside of Share Plans for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2019	1,698,000	\$ 2.58	
Options outstanding and exercisable at January 31, 2020	1,698,000	\$ 2.58	\$ 1,655,550

The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2020:

Range of Exercise Prices	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 2.58	1,698,000	2.50	\$ 2.58

Stock Awards

For stock awards granted to employees, directors and consultants that vest upon grant we recognize expense at the date of grant based on the grant date market price of the underlying common stock. We did not grant any stock awards that vested upon grant during the three months ended January 31, 2021 or 2020.

On May 8, 2018, a restricted stock award of 1,500,000 shares of common stock was granted under the 2018 Share Plan to our Chairman, President and Chief Executive Officer. The restricted stock award vests in its entirety upon achievement of a target trading price of \$11.00 per share of the Company's common stock before May 31, 2021. For restricted stock awards vesting upon achievement of a price target of our common stock we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). We did not record any compensation expense related to the restricted stock award during the three months ended January 31, 2021 and 2020.

Employee Stock Purchase Plan

The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan (“ESPP”) which permits eligible employees to purchase shares at not less than 85% of the market value of the Company’s common stock on the offering date or the purchase date of the applicable offering period, whichever is lower. The plan was adopted by our Board of Directors on August 13, 2018 and approved by our shareholders on September 27, 2018. During the three months ended January 31, 2021 and 2020, no shares were purchased under the ESPP.

Warrants

On October 30, 2020 we issued a warrant, expiring on October 30, 2025, to purchase 60,000 shares of common stock at \$2.06 per share, vesting over five months, to a consultant for investor relations services. We recorded consulting expense of approximately \$57,000 during the three months ended January 31, 2021, based on the fair value of the warrant on the date of grant recognized on a straight-line basis over the vesting period. We did not record any consulting expense related to warrants during the three months ended January 31, 2020. No warrants were issued during the three-month periods ended January 31, 2021 and 2020.

As of January 31, 2021, we also had warrants outstanding to purchase 500,000 shares of common stock at \$5.03 per share, issued during fiscal year 2017 and expiring on November 30, 2021.

Fair Value Measurements

**3 Months Ended
Jan. 31, 2021**

[Fair Value Disclosures](#)

[\[Abstract\]](#)

[Fair Value Measurements](#)

3. FAIR VALUE MEASUREMENTS

US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date.

Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.

Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's own assumptions about the assumptions a market participant would use in pricing the asset and liabilities.

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of January 31, 2021:

	Level 1	Level 2	Level 3	Total
Money market funds:				
Cash and cash equivalents	\$11,568,608	\$ -	\$ -	\$11,568,608
Certificates of deposit:				
Cash and cash equivalents	250,000	-	-	250,000
Short-term investments	-	2,000,000	-	2,000,000
Total financial assets	<u>\$11,818,608</u>	<u>\$ 2,000,000</u>	<u>\$ -</u>	<u>\$13,818,608</u>

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2020:

	Level 1	Level 2	Level 3	Total
Money market funds:				
Cash and cash equivalents	\$ 3,902,292	\$ -	\$ -	\$ 3,902,292
Certificates of deposit:				
Cash and cash equivalents	2,250,000	-	-	2,250,000
Short-term investments	-	2,640,000	-	2,640,000
Total financial assets	<u>\$ 6,152,292</u>	<u>\$ 2,640,000</u>	<u>\$ -</u>	<u>\$ 8,792,292</u>

Our non-financial assets that are measured on a non-recurring basis include our other assets which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value.

Accrued Expenses

**3 Months Ended
Jan. 31, 2021**

[Payables and Accruals \[Abstract\]](#)

[Accrued Expenses](#)

4. ACCRUED EXPENSES

Accrued expenses consist of the following as of:

	January 31, 2021	October 31, 2020
Payroll and related expenses	\$ 228,163	\$ 415,331
Accrued royalty and contingent legal fees	577,190	449,691
Accrued collaborative research and license expense	147,410	30,000
Accrued other	20,072	6,003
	<u>\$ 972,835</u>	<u>\$ 901,025</u>

**Net Loss Per Share of
Common Stock**

**3 Months Ended
Jan. 31, 2021**

Earnings Per Share

[Abstract]

**Net Loss Per Share of
Common Stock**

5. NET LOSS PER SHARE OF COMMON STOCK

Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the three months ended January 31, 2021 and 2020, were stock options to purchase 8,659,134 and 8,407,234 shares, respectively, and warrants to purchase 560,000 and 500,000 shares, respectively.

**Effect of Recently Adopted
and Issued Pronouncements**

**3 Months Ended
Jan. 31, 2021**

**Accounting Changes and
Error Corrections [Abstract]**

**Effect of Recently Adopted
and Issued Pronouncements**

6. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-02 (“ASU 2016-02”) Accounting Standards Codification Topic 842, Leases (ASC 842), which supersedes Topic 840, Leases, and which requires lessees to recognize most leases on the balance sheet. The new lease standard does not substantially change lessor accounting. For public companies, the standard was effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption was permitted. Lessees and lessors were required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance. In July 2018, FASB issued ASU 2018-11, Leases, which provides an additional transition option for an entity to apply the provisions of ASC 842 by recognizing a cumulative effect adjustment at the effective date of adoption without adjusting the prior comparative periods presented. The requirements of this standard include a significant increase in required disclosures. The Company adopted ASU 2016-02 on November 1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. See Note 8 regarding the accounting and disclosures related to our office lease.

Income Taxes

**3 Months Ended
Jan. 31, 2021**

[Income Tax Disclosure](#)

[\[Abstract\]](#)

[Income Taxes](#)

7. INCOME TAXES

We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets.

We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have no unrecognized income tax benefits as of January 31, 2021 and October 31, 2020 and we account for interest and penalties related to income tax matters, if any, in general and administrative expenses.

Leases

**3 Months Ended
Jan. 31, 2021**

[Leases \[Abstract\]](#)

[Leases](#)

8. LEASES

We lease approximately 2,000 square feet of office space at 3150 Almaden Expressway, San Jose, California (our principal executive offices) from an unrelated party pursuant to an operating lease that expires September 30, 2021. Our base rent is approximately \$5,000 per month and the lease provides for annual increases of approximately 3% and an escalation clause for increases in certain operating costs. Rent expense was approximately \$16,000 and \$16,000, respectively, for the three months ended January 31, 2021 and 2020.

On November 1, 2019, the Company adopted ASC 842, which increases transparency and comparability by recognizing a lessee's rights and obligations resulting from leases by recording them on the balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use ("ROU") assets and related operating lease liabilities on the balance sheet. The Company adopted the new guidance using the modified retrospective approach on November 1, 2019.

The Company elected the package of practical expedients permitted within the standard, which allow an entity to forgo reassessing (i) whether a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has also elected the short-term lease accounting policy under which Anixa would not recognize a lease liability or ROU asset for any lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that Anixa is more than reasonably certain to exercise.

For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The remaining 8-month lease term as of January 31, 2021 for the Company's lease includes the noncancelable period of the lease. The lease does not contain a Company option to extend the lease or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment.

Balance sheet information related to the Company's lease is presented below:

	Balance Sheet Location	January 31, 2021	October 31, 2020
Operating Lease:			
Right-of-use asset	Operating lease right-of-use asset	\$ 40,212	\$ 54,340
Right-of-use liability, current	Operating lease liability	40,836	55,198

As of January 31, 2021, the annual minimum lease payments of our operating lease liabilities were as follows:

	Operating Leases
2021 future minimum payments, undiscounted	\$ 43,008
Less: Imputed interest	(2,172)
Present value of future minimum lease payments	\$ 40,836

**Commitments and
Contingencies**

**3 Months Ended
Jan. 31, 2021**

**[Commitments and
Contingencies Disclosure](#)**

[\[Abstract\]](#)

**[Commitments and
Contingencies](#)**

9. COMMITMENTS AND CONTINGENCES

Litigation Matters

We are not involved in any litigation or other legal proceedings and management is not aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition.

Impact of Coronavirus Pandemic

On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had and are expected to continue to have a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and which the Company's partners operate and conduct their business. We are currently following the recommendations of local health authorities to minimize exposure risk for our team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While we have implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that our continuity plans will be successful.

We have already experienced certain disruptions to our business such as temporary closure of our offices and similar disruptions have occurred for our partners. Specifically, the outbreak has caused temporary shutdowns of the laboratories and other service providers that we rely on to develop our programs, and those laboratories and service providers that have been operating or that have begun operating recently have been doing so with more limited capacity due to social distancing requirements. As a result, our progress has been slowed and there is no assurance that we will be able to meet our previously announced timelines regarding the advancement of our programs.

The extent to which COVID-19 or any other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on our business, results of operations, financial condition and prospects.

Segment Information

**3 Months Ended
Jan. 31, 2021**

[Segment Reporting](#)

[\[Abstract\]](#)

[Segment Information](#)

10. SEGMENT INFORMATION

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) our legacy Patent Licensing activities. The following represents selected financial information for our segments for the three months ended January 31, 2021 and 2020 and as of January 31, 2021 and October 31, 2020:

	For the Three Months Ended	
	January 31,	
	2021	2020
Net loss:		
CAR-T Therapeutics	\$ (960,736)	\$ (630,333)
Cancer Vaccines	(906,336)	(195,596)
Anti-Viral Therapeutics	(480,806)	-
Cancer Diagnostics	(8,962)	(1,790,646)
Patent Licensing	124,463	-
Total	<u><u>\$(2,232,377)</u></u>	<u><u>\$(2,616,575)</u></u>
Total operating costs and expenses	\$ 2,745,631	\$ 2,629,869
Less non-cash share-based compensation	(986,099)	(1,021,334)
Operating costs and expenses excluding non-cash share-based compensation	<u><u>\$ 1,759,532</u></u>	<u><u>\$ 1,608,535</u></u>
Operating costs and expenses excluding non-cash share based compensation expense:		
CAR-T Therapeutics	\$ 557,680	\$ 346,341
Cancer Vaccines	537,988	98,270
Anti-Viral Therapeutics	270,256	-
Cancer Diagnostics	6,432	1,163,924
Patent Licensing	387,176	-
Total	<u><u>\$ 1,759,532</u></u>	<u><u>\$ 1,608,535</u></u>
	January 31,	October 31,
	2021	2020
Total assets:		
CAR-T Therapeutics	\$ 5,849,920	\$ 2,988,124

Cancer Vaccines	5,822,106	946,923
Anti-Viral Therapeutics	2,775,760	2,464,361
Cancer Diagnostics	85,463	2,869,529
Patent Licensing	71,153	184,027
Total	<u>\$14,604,402</u>	<u>\$ 9,452,964</u>

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

The Company's consolidated revenue of \$512,500 and inventor royalties, contingent legal fees, litigation and licensing expense of \$385,002 for the three months ended January 31, 2021 were solely related to our patent licensing segment which consists of our encrypted audio/video conference calling technology. All our revenue is generated domestically (United States) based on the country in which the licensee is located.

**Business and Funding
(Tables)**

**3 Months Ended
Jan. 31, 2021**

[Accounting Policies](#)

[\[Abstract\]](#)

[Schedule of Changes in
Noncontrolling Interest](#)

Noncontrolling interest represents Wistar's equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2021:

Balance, October 31, 2020	\$ (496,983)
Net loss attributable to noncontrolling interest	(24,086)
Balance, January 31, 2021	<u>\$ (521,069)</u>

**Stock Based Compensation
(Tables)**

**3 Months Ended
Jan. 31, 2021**

[Schedule of Option Activity](#)

Information regarding stock options that were granted outside of share plans for the three months ended January 31, 2021 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2020	1,698,000	\$ 2.58	
Options outstanding and exercisable at January 31, 2021	1,698,000	\$ 2.58	\$ 1,825,350

Information regarding stock options that were granted outside of Share Plans for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2019	1,698,000	\$ 2.58	
Options outstanding and exercisable at January 31, 2020	1,698,000	\$ 2.58	\$ 1,655,550

[Schedule of Outstanding and
Exercisable](#)

The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2021:

Range of Exercise Prices	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 2.58	1,698,000	1.56	\$ 2.58

The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2020:

Range of Exercise Prices	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 2.58	1,698,000	2.50	\$ 2.58

[2003 Plan \[Member\]
Schedule of Option Activity](#)

Information regarding the 2003 Plan for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2019	400	\$ 17.00	
Forfeited/Expired	(400)	\$ 17.00	
Options outstanding and exercisable at January 31, 2020	-	\$ -0-	\$ -0-

[2010 Plan \[Member\]
Schedule of Option Activity](#)

Information regarding the 2010 Share Plan for the three months ended January 31, 2021 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2020	1, 1,907,534	\$ 2.82	
Exercised	(6,000)	\$ 2.32	
Forfeited/Expired	(400)	\$ 5.75	
Options outstanding at January 31, 2021	1 1,901,134	\$ 2.82	\$ 1,906,253
Options exercisable at January 31, 2021	1, 1,823,634	\$ 2.83	\$ 1,822,053

Information regarding the 2010 Share Plan for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options Outstanding at October 31, 2019	1,998,668	\$ 2.80	
Exercised	(18,900)	\$ 1.51	
Forfeited/Expired	(5,534)	\$ 2.58	
Options Outstanding at January 31, 2020	1,974,234	\$ 2.81	\$ 1,810,395
Options Exercisable at January 31, 2020	1,721,734	\$ 2.86	\$ 1,542,195

[Schedule of Outstanding and
Exercisable](#)

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2021:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 0.67 - \$ 2.30	544,000	5.22	\$ 1.56	516,500	5.15	\$ 1.60

\$ 2.58 - \$ 3.13	833,000	3.11	\$ 2.79	833,000	3.54	\$ 2.79
\$ 3.46 - \$ 5.30	524,134	7.11	\$ 4.17	474,134	7.07	\$ 4.25

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2020:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price
		(in years)			(in years)	
\$ 0.67 - \$2.30	561,500	6.28	\$ 1.56	464,000	6.03	\$ 1.69
\$ 2.58 - \$ 3.13	878,200	3.43	\$ 2.79	878,200	3.97	\$ 2.79
\$ 3.46 - \$ 5.75	534,534	7.94	\$ 4.16	379,534	7.76	\$ 4.45

[2018 Plan \[Member\]](#)
[Schedule of Option Activity](#)

Information regarding the 2018 Share Plan for the three months ended January 31, 2021 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options outstanding at October 31, 2020	4,346,661	\$ 3.69	
Granted	1,130,000	\$ 2.83	
Exercised	(23,880)	\$ 3.78	
Forfeited/Expired	(392,781)	\$ 3.70	
Options outstanding at January 31, 2021	5,060,000	\$ 3.49	\$ 1,184,900
Options exercisable at January 31, 2021	2,312,640	\$ 3.69	\$ 147,579

Information regarding the 2018 Share Plan for the three months ended January 31, 2020 is as follows:

	Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Options Outstanding at October 31, 2019	3,935,500	\$ 3.74	
Granted	800,000	\$ 3.85	
Options Outstanding at January 31, 2020	4,735,000	\$ 3.76	\$ -0-
Options Exercisable at January 31, 2020	1,798,616	\$ 3.74	\$ -0-

[Schedule of Outstanding and Exercisable](#)

The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2021:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average	Weighted Average	Number Exercisable	Weighted Average	Weighted Average

		Remaining Contractual Life (in years)	Exercise Price		Remaining Contractual Life (in years)	Exercise Price
\$ 2.09 - \$3.70	3,975,000	8.12	\$ 3.38	1,664,862	7.47	\$ 3.61
\$ 3.84 - \$4.61	1,085,000	7.95	\$ 3.90	647,778	7.66	\$ 3.92

The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2020:

Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
\$ 3.70	3,100,000	8.27	\$ 3.70	1,433,334	8.27	\$ 3.70
\$ 3.84 - \$4.61	1,635,000	9.17	\$ 3.88	365,282	8.32	\$ 3.92

**Fair Value Measurements
(Tables)**

**3 Months Ended
Jan. 31, 2021**

[Fair Value Disclosures](#)

[\[Abstract\]](#)

[Schedule of Fair Value
Measurements](#)

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of January 31, 2021:

	Level 1	Level 2	Level 3	Total
Money market funds:				
Cash and cash equivalents	\$11,568,608	\$ -	\$ -	\$11,568,608
Certificates of deposit:				
Cash and cash equivalents	250,000	-	-	250,000
Short-term investments	-	2,000,000	-	2,000,000
Total financial assets	\$11,818,608	\$ 2,000,000	\$ -	\$13,818,608

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2020:

	Level 1	Level 2	Level 3	Total
Money market funds:				
Cash and cash equivalents	\$ 3,902,292	\$ -	\$ -	\$ 3,902,292
Certificates of deposit:				
Cash and cash equivalents	2,250,000	-	-	2,250,000
Short-term investments	-	2,640,000	-	2,640,000
Total financial assets	\$ 6,152,292	\$ 2,640,000	\$ -	\$ 8,792,292

Accrued Expenses (Tables)

**3 Months Ended
Jan. 31, 2021**

[Payables and Accruals \[Abstract\]](#)
[Schedule of Accrued Expenses](#)

Accrued expenses consist of the following as of:

	January 31, 2021	October 31, 2020
Payroll and related expenses	\$ 228,163	\$ 415,331
Accrued royalty and contingent legal fees	577,190	449,691
Accrued collaborative research and license expense	147,410	30,000
Accrued other	20,072	6,003
	<u>\$ 972,835</u>	<u>\$ 901,025</u>

Leases (Tables)

3 Months Ended Jan. 31, 2021

[Leases \[Abstract\]](#) [Schedule of Operating Lease](#)

Balance sheet information related to the Company's lease is presented below:

	Balance Sheet Location	January 31, 2021	October 31, 2020
Operating Lease:			
Right-of-use asset	Operating lease right-of-use asset	\$ 40,212	\$ 54,340
Right-of-use liability, current	Operating lease liability	40,836	55,198

[Schedule of Minimum Lease Payments](#)

As of January 31, 2021, the annual minimum lease payments of our operating lease liabilities were as follows:

	Operating Leases
2021 future minimum payments, undiscounted	\$ 43,008
Less: Imputed interest	(2,172)
Present value of future minimum lease payments	<u>\$ 40,836</u>

**Segment Information
(Tables)**

**3 Months Ended
Jan. 31, 2021**

[Segment Reporting
\[Abstract\]
Schedule of Segment
Information](#)

The following represents selected financial information for our segments for the three months ended January 31, 2021 and 2020 and as of January 31, 2021 and October 31, 2020:

	For the Three Months Ended January 31,	
	2021	2020
Net loss:		
CAR-T Therapeutics	\$ (960,736)	\$ (630,333)
Cancer Vaccines	(906,336)	(195,596)
Anti-Viral Therapeutics	(480,806)	-
Cancer Diagnostics	(8,962)	(1,790,646)
Patent Licensing	124,463	-
Total	<u><u>\$(2,232,377)</u></u>	<u><u>\$(2,616,575)</u></u>
Total operating costs and expenses	\$ 2,745,631	\$ 2,629,869
Less non-cash share-based compensation	(986,099)	(1,021,334)
Operating costs and expenses excluding non-cash share-based compensation	<u><u>\$ 1,759,532</u></u>	<u><u>\$ 1,608,535</u></u>
Operating costs and expenses excluding non-cash share based compensation expense:		
CAR-T Therapeutics	\$ 557,680	\$ 346,341
Cancer Vaccines	537,988	98,270
Anti-Viral Therapeutics	270,256	-
Cancer Diagnostics	6,432	1,163,924
Patent Licensing	387,176	-
Total	<u><u>\$ 1,759,532</u></u>	<u><u>\$ 1,608,535</u></u>
	January 31,	October 31,
	2021	2020
Total assets:		
CAR-T Therapeutics	\$ 5,849,920	\$ 2,988,124
Cancer Vaccines	5,822,106	946,923
Anti-Viral Therapeutics	2,775,760	2,464,361
Cancer Diagnostics	85,463	2,869,529
Patent Licensing	71,153	184,027
Total	<u><u>\$14,604,402</u></u>	<u><u>\$ 9,452,964</u></u>

Business and Funding (Details Narrative) - USD (\$)	3 Months Ended	
	Jan. 31, 2021	Jan. 31, 2020
Shares of common stock, value	\$ 5,956,596	\$ 1,751,983
Our at-the-Market Equity Offerings [Member]		
Net of expenses	\$ 5,957,000	
Sale of shares of common stock	1,900,547	
An at-the-Market Equity Offerings [Member]		
Shares of common stock, value	\$ 50,000,000	
Sale of shares of common stock, value	\$ 34,670,000	
Wistar Institute [Member]		
Ownership Percentage	5.00%	

**Business and Funding -
Schedule of Changes in
Noncontrolling Interest
(Details) - USD (\$)**

3 Months Ended

Jan. 31, 2021 Jan. 31, 2020

[Accounting Policies \[Abstract\]](#)

Balance	\$ (496,983)	
Net loss attributable to noncontrolling interest	(24,086)	\$ (24,032)
Balance	\$ (521,069)	

Stock Based Compensation (Details Narrative)	Oct. 30, 2020 \$/ shares shares	May 08, 2018 \$/ shares shares	1 Months	3 Months	
			Ended	Ended	Jan. 31, 2020 USD (\$) \$/ shares shares
	Oct. 31, 2018 Days \$/ shares shares		Oct. 31, 2021 USD (\$) \$/ shares shares	Jan. 31, 2021 USD (\$) \$/ shares shares	
Stock option compensation to employees and directors \$				\$ 874,862	\$ 963,880
Weighted average exercise per share \$ / shares					
Shares options, granted					
Stock options exercised \$				\$ 104,224	\$ 28,480
Warrants [Member]					
Vesting period	5				
Warrant expiration date	Oct. 30, 2025			Nov. 30, 2021	
Warrants purchase of common stock shares	60,000				
Warrant exercise price \$ / shares	\$ 2.06			\$ 5.03	
Consulting expense \$				\$ 57,000	
Warrants issued					
Warrants outstanding				500,000	
Stock Option [Member]					
Stock options exercised, shares				29,880	18,900
Stock options exercised \$				\$ 104,000	\$ 28,000
2018 Plan [Member]					
Weighted average exercise per share \$ / shares				\$ 3.78	
Shares options, granted				1,130,000	800,000
Stock options exercised, shares				23,880	
Shares available for future grants				2,000,000	
First Tranche [Member]					
Option to purchase common stock			500,000		
Weighted average exercise per share \$ / shares			\$ 5.00		
Consecutive trading days Days			20		
Employees and Directors [Member] Minimum [Member]					
Vesting period				1 year	
Employees and Directors [Member] Maximum [Member]					
Vesting period				4 years	
Chairman, President and Chief Executive Officer [Member]					
Option to purchase common stock			1,500,000		

Expiration date	May 31, 2021	
Chairman, President and Chief Executive Officer [Member] 2018 Plan [Member] Restricted Stock [Member]		
Option to purchase common stock	1,500,000	
Weighted average exercise per share \$ / shares	\$ 11.00	
Expiration date	May 31, 2021	
Chairman, President and Chief Executive Officer [Member] Minimum [Member]		
Weighted average exercise per share \$ / shares	\$ 5.00	
Service period	3 months	
Chairman, President and Chief Executive Officer [Member] Maximum [Member]		
Weighted average exercise per share \$ / shares	\$ 8.00	
Service period	7 months	
Consultants [Member]		
Stock option compensation to employees and directors \$		\$ 57,000 \$ 54,000
Employees and Consultants [Member] 2018 Plan [Member]		
Shares options, granted		1,130,000 800,000
Employees and Consultants [Member] Minimum [Member] 2018 Plan [Member]		
Exercise price \$ / shares		\$ 2.83
Employees and Consultants [Member] Maximum [Member] 2018 Plan [Member]		
Exercise price \$ / shares		\$ 4.04

**Stock Based Compensation -
Schedule of Option Activity
(Details) - USD (\$)**

**3 Months Ended
Jan. 31, 2021 Jan. 31, 2020**

<u>Shares, Options outstanding, Beginning balance</u>	1,698,000	1,698,000
<u>Shares, Options, Granted</u>		
<u>Shares, Options, Forfeited/Expired</u>		
<u>Shares, Options outstanding and Exercisable</u>	1,698,000	1,698,000
<u>Weighted Average Exercise Price Per Share, Outstanding Beginning balance</u>	\$ 2.58	\$ 2.58
<u>Weighted Average Exercise Price Per Share, Exercised</u>		
<u>Weighted Average Exercise Price Per Share, Outstanding and Exercisable</u>	\$ 2.58	\$ 2.58
<u>Aggregate Intrinsic Value, Outstanding and Exercisable</u>	\$ 1,825,350	\$ 1,655,550
<u>2003 Plan [Member]</u>		
<u>Shares, Options outstanding, Beginning balance</u>	400	
<u>Shares, Options, Forfeited/Expired</u>	(400)	
<u>Shares, Options outstanding, Ending balance</u>		
<u>Weighted Average Exercise Price Per Share, Outstanding Beginning balance</u>	\$ 17.00	
<u>Weighted Average Exercise Price Per Share, Forfeited/Expired</u>	17.00	
<u>Weighted Average Exercise Price Per Share, Outstanding Ending balance</u>	\$ 0	
<u>Aggregate Intrinsic Value, Outstanding and Exercisable</u>	\$ 0	
<u>2010 Plan [Member]</u>		
<u>Shares, Options outstanding, Beginning balance</u>	11,907,534	1,998,668
<u>Shares, Options, Exercised</u>	(6,000)	(18,900)
<u>Shares, Options, Forfeited/Expired</u>	(400)	(5,534)
<u>Shares, Options outstanding, Ending balance</u>	11,901,134	1,974,234
<u>Shares, Options outstanding, Exercisable</u>	11,823,634	1,721,734
<u>Weighted Average Exercise Price Per Share, Outstanding Beginning balance</u>	\$ 2.82	\$ 2.80
<u>Weighted Average Exercise Price Per Share, Exercised</u>	2.32	1.51
<u>Weighted Average Exercise Price Per Share, Forfeited/Expired</u>	5.75	2.58
<u>Weighted Average Exercise Price Per Share, Outstanding Ending balance</u>	2.82	2.81
<u>Weighted Average Exercise Price Per Share, Exercisable</u>	\$ 2.83	\$ 2.86
<u>Aggregate Intrinsic Value, Outstanding Ending balance</u>	\$ 1,906,253	\$ 1,810,395
<u>Aggregate Intrinsic Value, Exercisable</u>	\$ 1,822,053	\$ 1,542,195
<u>2018 Plan [Member]</u>		
<u>Shares, Options outstanding, Beginning balance</u>	4,346,661	3,935,500
<u>Shares, Options, Granted</u>	1,130,000	800,000
<u>Shares, Options, Exercised</u>	(23,880)	
<u>Shares, Options, Forfeited/Expired</u>	(392,781)	
<u>Shares, Options outstanding, Ending balance</u>	5,060,000	4,735,000
<u>Shares, Options outstanding, Exercisable</u>	2,312,640	1,798,616
<u>Weighted Average Exercise Price Per Share, Outstanding Beginning balance</u>	\$ 3.69	\$ 3.74
<u>Weighted Average Exercise Price Per Share, Granted</u>	2.83	3.85
<u>Weighted Average Exercise Price Per Share, Exercised</u>	3.78	
<u>Weighted Average Exercise Price Per Share, Forfeited/Expired</u>	3.70	

<u>Weighted Average Exercise Price Per Share, Outstanding Ending balance</u>	3.49	3.76
<u>Weighted Average Exercise Price Per Share, Exercisable</u>	\$ 3.69	\$ 3.74
<u>Aggregate Intrinsic Value, Outstanding Ending balance</u>	\$ 1,184,900	\$ 0
<u>Aggregate Intrinsic Value, Exercisable</u>	\$ 147,579	\$ 0

**Stock Based Compensation -
Schedule of Outstanding and
Exercisable (Details) - \$ /
shares**

3 Months Ended

	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020	Oct. 31, 2019
<u>Number of Outstanding</u>			1,698,000	1,698,000
<u>Weighted Average Exercise Price</u>			\$ 2.58	\$ 2.58
<u>2010 Plan [Member]</u>				
<u>Number of Outstanding</u>	11,901,134	1,974,234	11,907,534	1,998,668
<u>Weighted Average Exercise Price</u>	\$ 2.82	\$ 2.81	\$ 2.82	\$ 2.80
<u>Number Exercisable, Options Exercisable</u>	11,823,634	1,721,734		
<u>Weighted Average Exercise Price, Options Exercisable</u>	\$ 2.83	\$ 2.86		
<u>2010 Plan [Member] Range 1 [Member]</u>				
<u>Range of Exercise Prices, Lower limit</u>	0.67	0.67		
<u>Range of Exercise Prices, Upper limit</u>	\$ 2.30	\$ 2.30		
<u>Number of Outstanding</u>	544,000	561,500		
<u>Weighted Average Remaining Contractual Life (in years)</u>	5 years 2 months 19 days	6 years 3 months 11 days		
<u>Weighted Average Exercise Price</u>	\$ 1.56	\$ 1.56		
<u>Number Exercisable, Options Exercisable</u>	516,500	464,000		
<u>Weighted Average Remaining Contractual Life (in years), Options Exercisable</u>	5 years 1 month 24 days	6 years 11 days		
<u>Weighted Average Exercise Price, Options Exercisable</u>	\$ 1.60	\$ 1.69		
<u>2010 Plan [Member] Range 2 [Member]</u>				
<u>Range of Exercise Prices, Lower limit</u>	2.58	2.58		
<u>Range of Exercise Prices, Upper limit</u>	\$ 3.13	\$ 3.13		
<u>Number of Outstanding</u>	833,000	878,200		
<u>Weighted Average Remaining Contractual Life (in years)</u>	3 years 1 month 9 days	3 years 5 months 5 days		
<u>Weighted Average Exercise Price</u>	\$ 2.79	\$ 2.79		
<u>Number Exercisable, Options Exercisable</u>	833,000	878,200		
<u>Weighted Average Remaining Contractual Life (in years), Options Exercisable</u>	3 years 6 months 14 days	3 years 11 months 19 days		
<u>Weighted Average Exercise Price, Options Exercisable</u>	\$ 2.79	\$ 2.79		
<u>2010 Plan [Member] Range 3 [Member]</u>				
<u>Range of Exercise Prices, Lower limit</u>	3.46	3.46		
<u>Range of Exercise Prices, Upper limit</u>	\$ 5.30	\$ 5.75		
<u>Number of Outstanding</u>	524,134	534,534		
<u>Weighted Average Remaining Contractual Life (in years)</u>	7 years 1 month 9 days	7 years 11 months 8 days		
<u>Weighted Average Exercise Price</u>	\$ 4.17	\$ 4.16		
<u>Number Exercisable, Options Exercisable</u>	474,134	379,534		

Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years 26 days	7 years 9 months 3 days		
Weighted Average Exercise Price, Options Exercisable	\$ 4.25	\$ 4.45		
2018 Plan [Member]				
Number of Outstanding	5,060,000	4,735,000	4,346,661	3,935,500
Weighted Average Exercise Price	\$ 3.49	\$ 3.76	\$ 3.69	\$ 3.74
Number Exercisable, Options Exercisable	2,312,640	1,798,616		
Weighted Average Exercise Price, Options Exercisable	\$ 3.69	\$ 3.74		
2018 Plan [Member] Range 1 [Member]				
Range of Exercise Prices, Lower limit	2.09			
Range of Exercise Prices, Upper limit	\$ 3.70			
Exercise Prices		3.70		
Number of Outstanding	3,975,000	3,100,000		
Weighted Average Remaining Contractual Life (in years)	8 years 1 month 13 days	8 years 3 months 8 days		
Weighted Average Exercise Price	\$ 3.38	\$ 3.70		
Number Exercisable, Options Exercisable	1,664,862	1,433,334		
Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years 11 months 12 days	8 years 3 months 8 days		
Weighted Average Exercise Price, Options Exercisable	\$ 3.61	\$ 3.70		
2018 Plan [Member] Range 2 [Member]				
Range of Exercise Prices, Lower limit	3.84	3.84		
Range of Exercise Prices, Upper limit	\$ 4.61	\$ 4.61		
Number of Outstanding	1,085,000	1,635,000		
Weighted Average Remaining Contractual Life (in years)	7 years 11 months 12 days	9 years 2 months 1 day		
Weighted Average Exercise Price	\$ 3.90	\$ 3.88		
Number Exercisable, Options Exercisable	647,778	365,282		
Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years 7 months 28 days	8 years 3 months 26 days		
Weighted Average Exercise Price, Options Exercisable	\$ 3.92	\$ 3.92		
Outside of Share Plans [Member] Range 1 [Member]				
Range of Exercise Prices, Lower limit	\$ 2.58	\$ 2.58		
Options Outstanding and Exercisable	1,698,000	1,698,000		
Weighted Average Remaining Contractual Life (in years)	1 year 6 months 21 days	2 years 6 months		
Weighted Average Exercise Price	\$ 2.58	\$ 2.58		

**Fair Value Measurements -
Schedule of Fair Value
Measurements (Details) -
USD (\$)**

Jan. 31, 2021 Oct. 31, 2020

<u>Money market funds: Cash and cash equivalents</u>	\$ 11,568,608	\$ 3,902,292
<u>Certificates of deposit: Cash and cash equivalents</u>	250,000	2,250,000
<u>Short-term investments</u>	2,000,000	2,640,000
<u>Total financial assets</u>	13,818,608	8,792,292
<u>Level 1 [Member]</u>		
<u>Money market funds: Cash and cash equivalents</u>	11,568,608	3,902,292
<u>Certificates of deposit: Cash and cash equivalents</u>	250,000	2,250,000
<u>Short-term investments</u>		
<u>Total financial assets</u>	11,818,608	6,152,292
<u>Level 2 [Member]</u>		
<u>Money market funds: Cash and cash equivalents</u>		
<u>Certificates of deposit: Cash and cash equivalents</u>		
<u>Short-term investments</u>	2,000,000	2,640,000
<u>Total financial assets</u>	2,000,000	2,640,000
<u>Level 3 [Member]</u>		
<u>Money market funds: Cash and cash equivalents</u>		
<u>Certificates of deposit: Cash and cash equivalents</u>		
<u>Short-term investments</u>		
<u>Total financial assets</u>		

**Accrued Expenses - Schedule
of Accrued Expenses
(Details) - USD (\$)**

Jan. 31, 2021 Oct. 31, 2020

Payables and Accruals [Abstract]

<u>Payroll and related expenses</u>	\$ 228,163	\$ 415,331
<u>Accrued royalty and contingent legal fees</u>	577,190	449,691
<u>Accrued collaborative research and license expense</u>	147,410	30,000
<u>Accrued other</u>	20,072	6,003
<u>Accrued expenses</u>	\$ 972,835	\$ 901,025

Net Loss Per Share of Common Stock (Details Narrative) - shares	3 Months Ended	
	Jan. 31, 2021	Jan. 31, 2020
Stock Options [Member]		
Antidilutive shares	8,659,134	8,407,234
Warrants [Member]		
Antidilutive shares	560,000	500,000

**Income Taxes (Details
Narrative) - USD (\$)**

Jan. 31, 2021 Jan. 31, 2020

[Income Tax Disclosure \[Abstract\]](#)

[Unrecognized income tax benefits, penalties](#)

Leases (Details Narrative)	3 Months Ended	
	Jan. 31, 2021 USD (\$)	Jan. 31, 2020 USD (\$) ft ²
Rent expenses	\$ 16,000	\$ 16,000
Almaden Expressway, San Jose [Member]		
Area of land ft²		2,000
Operating lease, expiration date	Sep. 30, 2021	
Rent expenses	\$ 5,000	
Rent percentage	3.00%	
Operating lease remaining term		8 months

**Leases - Schedule of
Operating Lease (Details) - Jan. 31, 2021 Oct. 31, 2020
USD (\$)**

[Leases \[Abstract\]](#)

<u>Right-of-use asset</u>	\$ 40,212	\$ 54,340
<u>Right-of-use liability, current</u>	\$ 40,836	\$ 55,198

**Leases - Schedule of
Minimum Lease Payments
(Details)**

**Jan. 31, 2021
USD (\$)**

Leases [Abstract]

<u>2021 future minimum payments, undiscounted</u>	\$ 43,008
<u>Less: Imputed interest</u>	(2,172)
<u>Present value of future minimum lease payments</u>	\$ 40,836

Segment Information
(Details Narrative)

3 Months Ended
Jan. 31, 2021 **Jan. 31, 2020**
USD (\$) **USD (\$)**
Numbers

[Segment Reporting \[Abstract\]](#)

[Number of Reportable Segments | Numbers](#)

5

[Revenues](#)

\$ 512,500

[Inventor royalties, contingent legal fees, litigation and licensing expenses](#)

\$ 385,002

**Segment Information -
Schedule of Segment
Information (Details) - USD
(\$)**

3 Months Ended

	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020
<u>Net Loss</u>	\$ (2,232,377)	\$ (2,616,575)	
<u>Total operating costs and expenses</u>	2,745,631	2,629,869	
<u>Less non-cash share-based compensation</u>	(986,099)	(1,021,334)	
<u>Operating costs and expenses excluding non-cash share-based compensation</u>	1,759,532	1,608,535	
<u>Total assets</u>	14,604,402	9,452,964	\$ 9,452,964
<u>CAR-T Therapeutics [Member]</u>			
<u>Net Loss</u>	(960,736)	(630,333)	
<u>Operating costs and expenses excluding non-cash share-based compensation</u>	557,680	346,341	
<u>Total assets</u>	5,849,920	2,988,124	
<u>Cancer Vaccines [Member]</u>			
<u>Net Loss</u>	(906,336)	(195,596)	
<u>Operating costs and expenses excluding non-cash share-based compensation</u>	537,988	98,270	
<u>Total assets</u>	5,822,106	946,923	
<u>Anti-Viral Therapeutics [Member]</u>			
<u>Net Loss</u>	(480,806)		
<u>Operating costs and expenses excluding non-cash share-based compensation</u>	270,256		
<u>Total assets</u>	2,775,760	2,464,361	
<u>Cancer Diagnostics [Member]</u>			
<u>Net Loss</u>	(8,962)	(1,790,646)	
<u>Operating costs and expenses excluding non-cash share-based compensation</u>	6,432	1,163,924	
<u>Total assets</u>	85,463	2,869,529	
<u>Patent Licensing [Member]</u>			
<u>Net Loss</u>	124,463		
<u>Operating costs and expenses excluding non-cash share-based compensation</u>	387,176		
<u>Total assets</u>	\$ 71,153	\$ 184,027	